1
|
Lewis R, Scott R, Bala B, Jahan H, Bartram J, Radu T. Household water use and greywater management in Khulna city, Bangladesh. Int J Hyg Environ Health 2024; 259:114376. [PMID: 38569415 DOI: 10.1016/j.ijheh.2024.114376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2023] [Revised: 03/06/2024] [Accepted: 03/29/2024] [Indexed: 04/05/2024]
Abstract
While substantial progress has been made in improving water and sanitation services in low- and middle-income countries, aligned basic services such as greywater, stormwater, and solid waste management have progressed little in recent decades. Data was collected in Khulna city, Bangladesh via a household survey (n = 192) of low-income areas exploring domestic water use and greywater volumes, characteristics, and disposal practices. Most households (71%) use a piped water supply for domestic purposes, supplemented by seasonal rainwater harvesting (26%) and greywater use (13%). Of the total water used by households (mean: 594 L/household/day and equivalent to 116 L/person/day), approximately 58% becomes greywater through bathing, dishwashing, religious practices, handwashing, laundry, and mopping. Greywater produced ranges from 61-1274 L/household/day, with a mean of 345 L/household/day and equivalent to 78.4 L/person/day. Greywater characteristics vary depending on the activity, individual behaviours and any products used during cooking, bathing, or cleaning. After generation, households dispose greywater to open drains (67%), nearby waterbodies (17%) directly to the ground (9%), or decentralised wastewater treatment system (7%). Without services for greywater management, greywater disposal may have considerable public and environmental health implications, necessitating careful attention and oversight from service-providers and stakeholders beyond the household-level.
Collapse
Affiliation(s)
- R Lewis
- School of Architecture, Building and Civil Engineering, Loughborough University, Loughborough, Leicestershire, LE11 3TU, UK.
| | - R Scott
- School of Architecture, Building and Civil Engineering, Loughborough University, Loughborough, Leicestershire, LE11 3TU, UK.
| | - B Bala
- WaterAid Bangladesh, House 97B, Road 25, Block A, Banani, Dhaka 1213, Bangladesh.
| | - H Jahan
- WaterAid Bangladesh, House 97B, Road 25, Block A, Banani, Dhaka 1213, Bangladesh.
| | - J Bartram
- School of Civil Engineering, University of Leeds, Woodhouse Lane, Leeds, LS2 9D, UK.
| | - T Radu
- School of Architecture, Building and Civil Engineering, Loughborough University, Loughborough, Leicestershire, LE11 3TU, UK.
| |
Collapse
|
2
|
Scott S, Grossman S, Scott R. Should acrylic dentures be embedded with a radiopaque marker? Br Dent J 2023; 235:595. [PMID: 37891289 DOI: 10.1038/s41415-023-6448-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/29/2023]
Affiliation(s)
- S Scott
- Torbay Hospital, Torbay and South Devon NHS Foundation Trust, Devon, UK.
| | - S Grossman
- Torbay Hospital, Torbay and South Devon NHS Foundation Trust, Devon, UK.
| | - R Scott
- Torbay Hospital, Torbay and South Devon NHS Foundation Trust, Devon, UK.
| |
Collapse
|
3
|
Dogan B, Pattison N, Scott R, Alinier G. A protocol for a scoping review of the use of mental simulation and full-scale simulation in practising healthcare decision-making skills of undergraduate nursing students. Nurse Educ Pract 2023; 71:103699. [PMID: 37441918 DOI: 10.1016/j.nepr.2023.103699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2023] [Revised: 05/30/2023] [Accepted: 05/31/2023] [Indexed: 07/15/2023]
Abstract
AIM This scoping review aims to explore the effect of FSS and mental simulation on the decision-making skills of nursing students. BACKGROUND Full-scale simulation (FSS) has been the most used simulation modality in nursing education due to its applicability to enhance both technical and non-technical skills. However, FSS can be excessively costly and other factors such as technophobia and lack of trained staff and support make FSS less accessible, especially for nursing education. Therefore, a novel mental simulation that is interactive and supported by visual elements can be a substitute for FSS, at least for some of the skills, such as clinical decision-making. Reviews comparing the effectiveness of FSS and mental simulation on decision-making skills in nursing students are lacking. Further knowledge on the effectiveness of these two modalities on decision-making skills for nursing students is needed to inform the nursing education curriculum and to decide between the two modalities. DESIGN This protocol adheres to the guidelines outlined in the PRISMA extension for scoping reviews (PRISMA-scr) checklist. METHOD The methodological framework for scoping reviews will be followed for this scoping review. Scopus, EBSCOhost the Cumulative Index to Nursing and Allied Health Literature (CINAHL), MEDLINE and for the grey literature ERIC and BASE will be searched for related studies. The search will be limited to January 2008 and April 2023 (up-to-date) and English. A detailed search strategy was developed with an experienced research information manager and this strategy will be adapted to each database. A single screening will be performed by an author who will screen all abstracts and titles and full-text publications. After the study selection step of the framework, the data from the included studies will be charted using a data extraction form. The data will be synthesised by comparing the effect of FSS and mental simulation on decision-making skills. CONCLUSION A synopsis of the publication on FSS and mental simulation on nurse students' decision-making skills will be useful for stakeholders when choosing between two modalities to deliver decision-making skills to nursing students and also help to inform the nursing education and simulation practice. SCOPING REVIEW REGISTRATION Protocols.io (doi: 10.17504/protocols.io.e6nvw57y7vmk/v1).
Collapse
Affiliation(s)
- Burcu Dogan
- School of Health and Social Work University of Hertfordshire Hatfield, Hertfordshire, UK
| | - Natalie Pattison
- School of Health and Social Work University of Hertfordshire Hatfield, Hertfordshire, UK; East & North Herts NHS Trust Stevenage, UK.
| | - Rebecca Scott
- School of Health and Social Work University of Hertfordshire Hatfield, Hertfordshire, UK
| | - Guillaume Alinier
- School of Health and Social Work University of Hertfordshire Hatfield, Hertfordshire, UK; Hamad Medical Corporation Ambulance Service Doha, Qatar; Weill Cornell Medicine - Qatar Doha, Qatar; Faculty of Health and Life Sciences, Northumbria University Newcastle Upon Tyne, UK
| |
Collapse
|
4
|
McLain J, Gott M, Greene J, Scott R, Vondrasek R. Sputter sample preparation for ion beam delivery of radium-223 at ATLAS. Rev Sci Instrum 2023; 94:063301. [PMID: 37862488 DOI: 10.1063/5.0137098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/30/2022] [Accepted: 05/23/2023] [Indexed: 10/22/2023]
Abstract
A radium-223 ion beam was delivered to an experiment from the electron cyclotron resonance ion source, ECR2, at the Argonne Tandem Linac Accelerator System (ATLAS). The radium-223 material was in a nitrate salt form within a vial, prior to being converted to a usable sputter sample. The sputter sample was produced using a new sample preparation method, where the radium nitrate was dissolved into a solution and pipetted onto pressed aluminum powder. This sample was then allowed to dry, distributing the radium-223 material throughout the sputter sample. Ion source operation using the radium sputter sample is described with the operating parameters listed. The intensity and energy requirements for this ion beam were 1 × 106 particles/s and 1.07 GeV, respectively. Because the intensity is relatively low compared to most experiments at ATLAS, previously developed accelerator mass spectrometry methods were used Scott et al. [Rev. Sci. Instrum. 87, 02A732 (2016)] to avoid the need for tuning of the low-intensity beam of interest. Handling of the radium material, as well as loading and unloading of the sputter sample from ECR2, required collaboration with Health Physics. Procedures were used and dry runs were carried out before, during, and after the experiment to ensure the safety of the workers. The processes used and lessons learned are described within.
Collapse
Affiliation(s)
- J McLain
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - M Gott
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - J Greene
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - R Scott
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - R Vondrasek
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| |
Collapse
|
5
|
Scott R, Oakley A. Benign Keratosis: A Useful Term? Dermatol Pract Concept 2023; 13:dpc.1302a115. [PMID: 37196289 DOI: 10.5826/dpc.1302a115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/09/2022] [Indexed: 05/19/2023] Open
Abstract
INTRODUCTION Seborrheic keratosis (SK), lichen planus-like keratosis (LPLK), and solar lentigo (SL) are common benign skin lesions. These lesions are frequently seen adjacent to each other or can arise from one another. They can sometimes be difficult to differentiate despite having distinct histopathological features. OBJECTIVES We evaluated dermoscopic images of 80 skin lesions to confirm the term 'benign keratosis' is useful for an undifferentiated SK/LPLK/SL where there are overlapping clinical and dermoscopic characteristics. METHODS Clinical and dermoscopic images were sourced from a teledermoscopy service database of 13,000 lesions in 7,000 patients. The database was queried for SK, SL or LPLK in sun-exposed sites. Each lesion was evaluated based on specific dermoscopic criteria and the results analyzed. RESULTS Lesions were identified with mixed clinical and dermoscopic criteria of SK and SL, and in some, dermoscopic criteria for LPLK were also present. CONCLUSIONS This study highlights the relationship between these lesions. We confirm the term 'benign keratosis' is useful for mixed lesions or for those that are difficult to classify.
Collapse
Affiliation(s)
- Rebecca Scott
- University of Aberdeen, Waikato Hospital, Hamilton, New Zealand
| | - Amanda Oakley
- Waikato District Health Board, Hamilton, New Zealand
- University of Auckland, Faculty of Medical and Health Science Medical School, Waikato Campus, Auckland, New Zealand
| |
Collapse
|
6
|
Kinoshita N, Paul M, Kashiv Y, Collon P, Deibel CM, DiGiovine B, Greene JP, Jiang CL, Marley ST, Pardo RC, Rehm KE, Robertson D, Scott R, Schmitt C, Tang XD, Vondrasek R, Yokoyama A. Retraction. Science 2023; 379:1307. [PMID: 36996231 DOI: 10.1126/science.adh7739] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/01/2023]
Affiliation(s)
- N Kinoshita
- Shimizu Corporation Institute of Technology, Tokyo, Japan
| | - M Paul
- Hebrew University of Jerusalem, Jerusalem, Israel
| | - Y Kashiv
- University of Notre Dame, Notre Dame, IN, USA
| | - P Collon
- University of Notre Dame, Notre Dame, IN, USA
| | - C M Deibel
- Louisiana State University, Baton Rouge, LA, USA
| | - B DiGiovine
- Los Alamos National Laboratory, Los Alamos, NM, USA
| | - J P Greene
- Argonne National Laboratory, Argonne, IL, USA
| | - C L Jiang
- Argonne National Laboratory, Argonne, IL, USA
| | - S T Marley
- Louisiana State University, Baton Rouge, LA, USA
| | - R C Pardo
- Argonne National Laboratory, Argonne, IL, USA
| | - K E Rehm
- Argonne National Laboratory, Argonne, IL, USA
| | - D Robertson
- University of Notre Dame, Notre Dame, IN, USA
| | - R Scott
- Argonne National Laboratory, Argonne, IL, USA
| | - C Schmitt
- University of Notre Dame, Notre Dame, IN, USA
| | - X D Tang
- Institute of Modern Physics, Lanzhou, China
| | - R Vondrasek
- Argonne National Laboratory, Argonne, IL, USA
| | - A Yokoyama
- Kanazawa University, Kakumamachi, Kanazawa, Ishikawa, Japan
| |
Collapse
|
7
|
Markowitz JE, Gillis WF, Jay M, Wood J, Harris RW, Cieszkowski R, Scott R, Brann D, Koveal D, Kula T, Weinreb C, Osman MAM, Pinto SR, Uchida N, Linderman SW, Sabatini BL, Datta SR. Spontaneous behaviour is structured by reinforcement without explicit reward. Nature 2023; 614:108-117. [PMID: 36653449 PMCID: PMC9892006 DOI: 10.1038/s41586-022-05611-2] [Citation(s) in RCA: 44] [Impact Index Per Article: 44.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2022] [Accepted: 11/30/2022] [Indexed: 01/19/2023]
Abstract
Spontaneous animal behaviour is built from action modules that are concatenated by the brain into sequences1,2. However, the neural mechanisms that guide the composition of naturalistic, self-motivated behaviour remain unknown. Here we show that dopamine systematically fluctuates in the dorsolateral striatum (DLS) as mice spontaneously express sub-second behavioural modules, despite the absence of task structure, sensory cues or exogenous reward. Photometric recordings and calibrated closed-loop optogenetic manipulations during open field behaviour demonstrate that DLS dopamine fluctuations increase sequence variation over seconds, reinforce the use of associated behavioural modules over minutes, and modulate the vigour with which modules are expressed, without directly influencing movement initiation or moment-to-moment kinematics. Although the reinforcing effects of optogenetic DLS dopamine manipulations vary across behavioural modules and individual mice, these differences are well predicted by observed variation in the relationships between endogenous dopamine and module use. Consistent with the possibility that DLS dopamine fluctuations act as a teaching signal, mice build sequences during exploration as if to maximize dopamine. Together, these findings suggest a model in which the same circuits and computations that govern action choices in structured tasks have a key role in sculpting the content of unconstrained, high-dimensional, spontaneous behaviour.
Collapse
Affiliation(s)
- Jeffrey E Markowitz
- Department of Neurobiology, Harvard Medical School, Boston, MA, USA
- Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA
| | | | - Maya Jay
- Department of Neurobiology, Harvard Medical School, Boston, MA, USA
| | - Jeffrey Wood
- Department of Neurobiology, Harvard Medical School, Boston, MA, USA
| | - Ryley W Harris
- Department of Neurobiology, Harvard Medical School, Boston, MA, USA
| | | | - Rebecca Scott
- Department of Neurobiology, Harvard Medical School, Boston, MA, USA
| | - David Brann
- Department of Neurobiology, Harvard Medical School, Boston, MA, USA
| | - Dorothy Koveal
- Department of Neurobiology, Harvard Medical School, Boston, MA, USA
| | - Tomasz Kula
- Department of Neurobiology, Harvard Medical School, Boston, MA, USA
| | - Caleb Weinreb
- Department of Neurobiology, Harvard Medical School, Boston, MA, USA
| | | | - Sandra Romero Pinto
- Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA, USA
- Center for Brain Science, Harvard University, Cambridge, MA, USA
| | - Naoshige Uchida
- Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA, USA
- Center for Brain Science, Harvard University, Cambridge, MA, USA
| | - Scott W Linderman
- Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA
- Department of Statistics, Stanford University, Stanford, CA, USA
| | - Bernardo L Sabatini
- Department of Neurobiology, Harvard Medical School, Boston, MA, USA
- Howard Hughes Medical Institute, Chevy Chase, MD, USA
| | | |
Collapse
|
8
|
Odetunde T, Sunny O, Scott R. Introduction of the Discharge Medicines Service (DMS) at acute NHS trust, does this go far enough? International Journal of Pharmacy Practice 2022. [DOI: 10.1093/ijpp/riac089.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Abstract
Abstract
Introduction
The Discharge Medicines Service (DMS) is one of several initiatives being implemented as part of the NHS 5-year plan's second year to relieve the load on hospital Accident and Emergency (A&E) departments. The DMS service specification states that patients who are considered to be at risk of medication-related harm should be electronically referred by the NHS Trust to a pharmacy for assistance with their medications within 24-48 hours of being discharged from the hospital. NHS England and NHS Improvement made available £1.2 million to ensure NHS trusts have appropriate software and functionality to send referrals to community pharmacy, but the funding is not available to private providers responsible for community hospital services. However, for the DMS service to strengthen and improve medicine safety across the NHS, there is a need to involve community hospital services run by private providers.
Aim
The aim of this study was to investigate the medicines related risk for patients discharged from Caterham Dene Hospital (CDH), a community hospital service.
Methods
A retrospective analysis of patient discharge summaries was carried out to determine whether there were changes in the patient’s medication prior to being discharged from East Surrey Hospital (ESH) to CDH and then to their home. The medical records of (N=183) patients who were admitted to CDH from ESH between 1st June 2021 - 31st December 2021 were identified. 22 patients who were re-admitted to ESH through A&E and 2 patients whose discharge letter could not be found in their medical record or had missing information were excluded. Patients who were discharged to another care setting, e.g. a care home, were also excluded from this study. A data collection form was used, and the data were transferred to Microsoft Excel for descriptive statistical analysis. As a service evaluation, ethical approval was not required.
Results
A total of 159 patients’ medical records and discharge summaries were analysed, of whom 97% of patients had changes in their medication after admission to CDH. The most frequent changes were either having medication stopped because it was no longer required, or medication started due to new diagnosis. The top two commonly identified drug classes are laxatives and opioids. 40% of all medicines that were changed were appropriate for DMS referral on discharge from CDH.
Discussion/Conclusion
Although a small-scale study, the findings demonstrate that it is important for private providers of community hospital services, such as First Community, to be included to deliver the DMS referral service. Further investigation is recommended to explore whether similar results would be achieved in other community hospital services run by private providers. In response to the discharge data shared, Surrey Heartland Integrated Care System made available funds to roll out the DMS service to CDH. First Community is the only private provider currently delivering the DMS service and between mid-June and July 2022 a total of 10 patients have been referred.
Collapse
Affiliation(s)
| | - O Sunny
- First Community Health and Care , UK
| | - R Scott
- First Community Health and Care , UK
| |
Collapse
|
9
|
Hope DCD, Hinds CE, Lopes T, Vincent ML, Shrewsbury JV, Yu ATC, Davies I, Scott R, Jones B, Murphy KG, Minnion JS, Sardini A, Carling D, Lutz TA, Bloom SR, Tan TMM, Owen BM. Hypoaminoacidemia underpins glucagon-mediated energy expenditure and weight loss. Cell Rep Med 2022; 3:100810. [PMID: 36384093 PMCID: PMC9729826 DOI: 10.1016/j.xcrm.2022.100810] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2021] [Revised: 09/26/2022] [Accepted: 10/13/2022] [Indexed: 11/17/2022]
Abstract
Glucagon analogs show promise as components of next-generation, multi-target, anti-obesity therapeutics. The biology of chronic glucagon treatment, in particular, its ability to induce energy expenditure and weight loss, remains poorly understood. Using a long-acting glucagon analog, G108, we demonstrate that glucagon-mediated body weight loss is intrinsically linked to the hypoaminoacidemia associated with its known amino acid catabolic action. Mechanistic studies reveal an energy-consuming response to low plasma amino acids in G108-treated mice, prevented by dietary amino acid supplementation and mimicked by a rationally designed low amino acid diet. Therefore, low plasma amino acids are a pre-requisite for G108-mediated energy expenditure and weight loss. However, preventing hypoaminoacidemia with additional dietary protein does not affect the ability of G108 to improve glycemia or hepatic steatosis in obese mice. These studies provide a mechanism for glucagon-mediated weight loss and confirm the hepatic glucagon receptor as an attractive molecular target for metabolic disease therapeutics.
Collapse
Affiliation(s)
- David C D Hope
- Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
| | - Charlotte E Hinds
- Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
| | - Tatiana Lopes
- Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
| | - Matthew L Vincent
- Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
| | - Jed V Shrewsbury
- Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
| | - Arthur T C Yu
- Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
| | - Iona Davies
- Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
| | - Rebecca Scott
- Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
| | - Ben Jones
- Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
| | - Kevin G Murphy
- Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
| | - James S Minnion
- Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
| | - Alessandro Sardini
- MRC London Institute of Medical Sciences, Imperial College London, London, UK
| | - David Carling
- MRC London Institute of Medical Sciences, Imperial College London, London, UK
| | - Thomas A Lutz
- Institute of Veterinary Physiology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
| | - Stephen R Bloom
- Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
| | - Tricia M M Tan
- Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
| | - Bryn M Owen
- Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
| |
Collapse
|
10
|
Fernandez G, Prastawa M, Scott R, Marami B, Shpalensky N, Madduri A, Cascetta K, Sawyer M, Chan M, Koll G, Malinowski D, De Angel R, Shtabsky A, Feliz A, Hansen T, Veremis B, Cordon-Cardo C, Zeineh J, Donovan M. Development and Validation of a Digital-Artificial Intelligent (AI) enabled Assay to predict early-stage breast cancer recurrence. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)01581-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
11
|
Kodate N, Kohli P, McGinn C, Scott R, Ross E, Treusch P, Maeda Y, Donnelly S, Leonard C, Cogan L, Mannan H, O’Shea D, Obayashi K, Masuyama S. 43 EXPLORING STAFF PERCEPTIONS AND ATTITUDES TO CARE AND CAREBOTS: THE CASE OF AN ORIGINAL AIR-DISINFECTION ROBOT IN IRELAND. Age Ageing 2022. [DOI: 10.1093/ageing/afac218.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The pandemic heightened the sense of security and safety in care settings, with cleanliness and infection control becoming an even more important aspect of care delivery. Although the impact of new welfare technology on health and social care has been discussed in recent years, few studies have reported the implementation processes or human-robot interactions in care facilities in different cultural settings. The aims of this interdisciplinary research therefore were to understand needs and aspects that have to be considered for implementing an assistive robot, and to explore user perceptions, and the process by which the robots are adopted in Ireland and Japan.
Methods
An original air-disinfection robot (V-Air) was developed by Akara Robotics, as part of research project “Harmonisation towards the establishment of Person-centred, Robotics-aided Care System” (Toyota Foundation, D18-ST-0005). Prior to its instalment in a rehabilitation centre in Dublin, semi-structured interviews were conducted, and observations carried out with seven care professionals, as they interacted with V-Air. The robot was then trialled for eight weeks (March-May 2022) in selected areas of the facility. After four weeks, the users filled out the System Usability Score and were asked questions at the end of the trial. Their scores and answers to the questions revealed staff perceptions and attitudes to care robots.
Results
Overall, the users had positive perceptions of V-Air and its usability. Initial differences existed in staff’s confidence levels, depending on prior experiences with technologies. Collective sensemaking was observed, particularly, around care delivery processes and robot functionalities. The adoption process was facilitated by several factors such as the timing of introduction, user-centred design, concept of care and organisational support.
Conclusion
The findings suggest that the introduction of care robots in care settings can offer an additional layer of organisational safety, while highlighting the significance of the iterative process in adopting assistive technologies.
Collapse
Affiliation(s)
- N Kodate
- University College Dublin School of Social Policy, Social Work and Social Justice, , Dublin, Ireland
- Universal Accessibility & Ageing Research Centre , Nishitokyo, Japan
- Hokkaido University Public Policy Research Center, , Sapporo, Japan
- L’École des Hautes Etudes En Sciences Sociales, Fondation France Japon , Paris, France
- University of Tokyo Institute for Future Initiatives, , Tokyo, Japan
| | - P Kohli
- Maynooth University Department of Sociology, , Maynooth, Ireland
| | - C McGinn
- Trinity College Dublin Department of Mechanical, Manufacturing & Biomedical Engineering, , Dublin, Ireland
- Akara Robotics , Dublin, Ireland
| | - R Scott
- Akara Robotics , Dublin, Ireland
| | - E Ross
- Royal Hospital Donnybrook , Dublin, Ireland
| | - P Treusch
- Trinity College Dublin Trinity Long Room Hub, , Dublin, Ireland
| | - Y Maeda
- Technological University Dublin , Dublin, Ireland
| | - S Donnelly
- University College Dublin School of Social Policy, Social Work and Social Justice, , Dublin, Ireland
| | - C Leonard
- Royal Hospital Donnybrook , Dublin, Ireland
| | - L Cogan
- Royal Hospital Donnybrook , Dublin, Ireland
| | - H Mannan
- University College Dublin School of Nursing, Midwifery and Health System, , Dublin, Ireland
| | - D O’Shea
- St. Vincent’s University Hospital , Dublin, Ireland
| | - K Obayashi
- Nihon Fukushi University Faculty of Healthcare Management, , Mihama, Japan
- Social Welfare Corporation Tokyo Seishin-kai , Nishitokyo, Japan
| | | |
Collapse
|
12
|
Arbour G, Perreault S, Prudhomme N, Teira P, Scott R, Nguyen C. P.216 Two interesting and unique cases of acquired neuropathies in pediatrics. Neuromuscul Disord 2022. [DOI: 10.1016/j.nmd.2022.07.384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
13
|
Mouchahoir T, Schiel JE, Rogers R, Heckert A, Place BJ, Ammerman A, Li X, Robinson T, Schmidt B, Chumsae CM, Li X, Manuilov AV, Yan B, Staples GO, Ren D, Veach AJ, Wang D, Yared W, Sosic Z, Wang Y, Zang L, Leone AM, Liu P, Ludwig R, Tao L, Wu W, Cansizoglu A, Hanneman A, Adams GW, Perdivara I, Walker H, Wilson M, Brandenburg A, DeGraan-Weber N, Gotta S, Shambaugh J, Alvarez M, Yu XC, Cao L, Shao C, Mahan A, Nanda H, Nields K, Nightlinger N, Niu B, Wang J, Xu W, Leo G, Sepe N, Liu YH, Patel BA, Richardson D, Wang Y, Tizabi D, Borisov OV, Lu Y, Maynard EL, Gruhler A, Haselmann KF, Krogh TN, Sönksen CP, Letarte S, Shen S, Boggio K, Johnson K, Ni W, Patel H, Ripley D, Rouse JC, Zhang Y, Daniels C, Dawdy A, Friese O, Powers TW, Sperry JB, Woods J, Carlson E, Sen KI, Skilton SJ, Busch M, Lund A, Stapels M, Guo X, Heidelberger S, Kaluarachchi H, McCarthy S, Kim J, Zhen J, Zhou Y, Rogstad S, Wang X, Fang J, Chen W, Yu YQ, Hoogerheide JG, Scott R, Yuan H. Attribute Analytics Performance Metrics from the MAM Consortium Interlaboratory Study. J Am Soc Mass Spectrom 2022; 33:1659-1677. [PMID: 36018776 PMCID: PMC9460773 DOI: 10.1021/jasms.2c00129] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/11/2022] [Revised: 08/01/2022] [Accepted: 08/02/2022] [Indexed: 05/23/2023]
Abstract
The multi-attribute method (MAM) was conceived as a single assay to potentially replace multiple single-attribute assays that have long been used in process development and quality control (QC) for protein therapeutics. MAM is rooted in traditional peptide mapping methods; it leverages mass spectrometry (MS) detection for confident identification and quantitation of many types of protein attributes that may be targeted for monitoring. While MAM has been widely explored across the industry, it has yet to gain a strong foothold within QC laboratories as a replacement method for established orthogonal platforms. Members of the MAM consortium recently undertook an interlaboratory study to evaluate the industry-wide status of MAM. Here we present the results of this study as they pertain to the targeted attribute analytics component of MAM, including investigation into the sources of variability between laboratories and comparison of MAM data to orthogonal methods. These results are made available with an eye toward aiding the community in further optimizing the method to enable its more frequent use in the QC environment.
Collapse
Affiliation(s)
- Trina Mouchahoir
- National
Institute of Standards and Technology, 100 Bureau Dr, Gaithersburg, Maryland 20899, United States
- Institute
for Bioscience and Biotechnology Research, 9600 Gudelsky Dr, Rockville, Maryland 20850, United States
| | - John E. Schiel
- National
Institute of Standards and Technology, 100 Bureau Dr, Gaithersburg, Maryland 20899, United States
- Institute
for Bioscience and Biotechnology Research, 9600 Gudelsky Dr, Rockville, Maryland 20850, United States
| | - Rich Rogers
- Just-Evotech
Biologics, Inc., 401
Terry Ave N., Seattle, Washington 98109, United States
| | - Alan Heckert
- National
Institute of Standards and Technology, 100 Bureau Dr, Gaithersburg, Maryland 20899, United States
| | - Benjamin J. Place
- National
Institute of Standards and Technology, 100 Bureau Dr, Gaithersburg, Maryland 20899, United States
| | - Aaron Ammerman
- AbbVie, 1000 Gateway
Blvd, South San Francisco, California 94080, United States
| | - Xiaoxiao Li
- AbbVie, 1000 Gateway
Blvd, South San Francisco, California 94080, United States
| | - Tom Robinson
- AbbVie, 1000 Gateway
Blvd, South San Francisco, California 94080, United States
| | - Brian Schmidt
- AbbVie, 1000 Gateway
Blvd, South San Francisco, California 94080, United States
| | - Chris M. Chumsae
- AbbVie, 100 Research Drive, Worcester, Massachusetts 01605, United States
| | - Xinbi Li
- AbbVie, 100 Research Drive, Worcester, Massachusetts 01605, United States
| | - Anton V. Manuilov
- AbbVie, 100 Research Drive, Worcester, Massachusetts 01605, United States
| | - Bo Yan
- AbbVie, 100 Research Drive, Worcester, Massachusetts 01605, United States
| | - Gregory O. Staples
- Agilent
Technologies, 5301 Stevens Creek Blvd, Santa Clara, California 95008, United States
| | - Da Ren
- Amgen, One Amgen Center Dr, Thousand
Oaks, California 91320, United States
| | - Alexander J. Veach
- Amgen, One Amgen Center Dr, Thousand
Oaks, California 91320, United States
| | - Dongdong Wang
- BioAnalytix, 790 Memorial Dr, Cambridge, Massachusetts 02139, United States
| | - Wael Yared
- BioAnalytix, 790 Memorial Dr, Cambridge, Massachusetts 02139, United States
| | - Zoran Sosic
- Biogen, 125 Broadway, Cambridge, Massachusetts 02142, United States
| | - Yan Wang
- Biogen, 125 Broadway, Cambridge, Massachusetts 02142, United States
| | - Li Zang
- Biogen, 125 Broadway, Cambridge, Massachusetts 02142, United States
| | - Anthony M. Leone
- Bristol-Myers
Squibb, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States
| | - Peiran Liu
- Bristol-Myers
Squibb, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States
| | - Richard Ludwig
- Bristol-Myers
Squibb, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States
| | - Li Tao
- Bristol-Myers
Squibb, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States
| | - Wei Wu
- Bristol-Myers
Squibb, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States
| | - Ahmet Cansizoglu
- Charles
River Laboratories, 8
Henshaw Street, Shrewsbury, Massachusetts 01801, United States
| | - Andrew Hanneman
- Charles
River Laboratories, 8
Henshaw Street, Shrewsbury, Massachusetts 01801, United States
| | - Greg W. Adams
- FUJIFILM
Diosynth Biotechnologies, 101 J. Morris Commons Ln, Morrisville, North Carolina 27560, United States
| | - Irina Perdivara
- FUJIFILM
Diosynth Biotechnologies, 101 J. Morris Commons Ln, Morrisville, North Carolina 27560, United States
| | - Hunter Walker
- FUJIFILM
Diosynth Biotechnologies, 101 J. Morris Commons Ln, Morrisville, North Carolina 27560, United States
| | - Margo Wilson
- FUJIFILM
Diosynth Biotechnologies, 101 J. Morris Commons Ln, Morrisville, North Carolina 27560, United States
| | | | - Nick DeGraan-Weber
- Genedata, 750 Marrett Road, One Cranberry
Hill, Lexington, Massachusetts 02421, United States
| | - Stefano Gotta
- Genedata, Margarethenstrasse 38, Basel, 4053, Switzerland
| | - Joe Shambaugh
- Genedata, 750 Marrett Road, One Cranberry
Hill, Lexington, Massachusetts 02421, United States
| | - Melissa Alvarez
- Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - X. Christopher Yu
- Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - Li Cao
- GSK, 709
Swedeland Rd, King of Prussia, Pennsylvania 19406, United States
| | - Chun Shao
- GSK, 709
Swedeland Rd, King of Prussia, Pennsylvania 19406, United States
| | - Andrew Mahan
- Janssen, 1400 McKean Road, Springhouse, Pennsylvania 19477, United States
| | - Hirsh Nanda
- Janssen, 1400 McKean Road, Springhouse, Pennsylvania 19477, United States
| | - Kristen Nields
- Janssen, 1400 McKean Road, Springhouse, Pennsylvania 19477, United States
| | - Nancy Nightlinger
- Just-Evotech
Biologics, Inc., 401
Terry Ave N., Seattle, Washington 98109, United States
| | - Ben Niu
- AstraZeneca, One MedImmune Way, Gaithersburg, Maryland 20878, United
States
| | - Jihong Wang
- AstraZeneca, One MedImmune Way, Gaithersburg, Maryland 20878, United
States
| | - Wei Xu
- AstraZeneca, One MedImmune Way, Gaithersburg, Maryland 20878, United
States
| | - Gabriella Leo
- EMD Serono an affiliate of Merck KGaA, Darmstadt, Germany, Via Luigi Einaudi 11, Guidonia Montecelio (Roma), 00012, Italy
| | - Nunzio Sepe
- EMD Serono an affiliate of Merck KGaA, Darmstadt, Germany, Via Luigi Einaudi 11, Guidonia Montecelio (Roma), 00012, Italy
| | - Yan-Hui Liu
- Merck
& Co., Inc.., 2000 Galloping Hill Rd, Kenilworth, New Jersey 07033, United States
| | - Bhumit A. Patel
- Merck
& Co., Inc.., 2000 Galloping Hill Rd, Kenilworth, New Jersey 07033, United States
| | - Douglas Richardson
- Merck
& Co., Inc.., 2000 Galloping Hill Rd, Kenilworth, New Jersey 07033, United States
| | - Yi Wang
- Merck
& Co., Inc.., 2000 Galloping Hill Rd, Kenilworth, New Jersey 07033, United States
| | - Daniela Tizabi
- National
Institute of Standards and Technology, 100 Bureau Dr, Gaithersburg, Maryland 20899, United States
- Institute
for Bioscience and Biotechnology Research, 9600 Gudelsky Dr, Rockville, Maryland 20850, United States
| | - Oleg V. Borisov
- Novavax,
Inc., 20 Firstfield Road, Gaithersburg, Maryland 20878, United States
| | - Yali Lu
- Novavax,
Inc., 20 Firstfield Road, Gaithersburg, Maryland 20878, United States
| | - Ernest L. Maynard
- Novavax,
Inc., 20 Firstfield Road, Gaithersburg, Maryland 20878, United States
| | | | | | | | | | - Simon Letarte
- Pfizer, 375 N Field Dr, Lake Forest, Illinois 60045, United
States
| | - Sean Shen
- Pfizer, 375 N Field Dr, Lake Forest, Illinois 60045, United
States
| | - Kristin Boggio
- Pfizer, 1 Burtt Rd, Andover, Massachusetts 01810, United States
| | - Keith Johnson
- Pfizer, 1 Burtt Rd, Andover, Massachusetts 01810, United States
| | - Wenqin Ni
- Pfizer, 1 Burtt Rd, Andover, Massachusetts 01810, United States
| | - Himakshi Patel
- Pfizer, 1 Burtt Rd, Andover, Massachusetts 01810, United States
| | - David Ripley
- Pfizer, 1 Burtt Rd, Andover, Massachusetts 01810, United States
| | - Jason C. Rouse
- Pfizer, 1 Burtt Rd, Andover, Massachusetts 01810, United States
| | - Ying Zhang
- Pfizer, 1 Burtt Rd, Andover, Massachusetts 01810, United States
| | - Carly Daniels
- Pfizer, 700 Chesterfield
Pkwy West, Chesterfield, Missouri 63017, United
States
| | - Andrew Dawdy
- Pfizer, 700 Chesterfield
Pkwy West, Chesterfield, Missouri 63017, United
States
| | - Olga Friese
- Pfizer, 700 Chesterfield
Pkwy West, Chesterfield, Missouri 63017, United
States
| | - Thomas W. Powers
- Pfizer, 700 Chesterfield
Pkwy West, Chesterfield, Missouri 63017, United
States
| | - Justin B. Sperry
- Pfizer, 700 Chesterfield
Pkwy West, Chesterfield, Missouri 63017, United
States
| | - Josh Woods
- Pfizer, 700 Chesterfield
Pkwy West, Chesterfield, Missouri 63017, United
States
| | - Eric Carlson
- Protein
Metrics, Inc., 20863
Stevens Creek Blvd, Cupertino, California 95014, United States
| | - K. Ilker Sen
- Protein
Metrics, Inc., 20863
Stevens Creek Blvd, Cupertino, California 95014, United States
| | - St John Skilton
- Protein
Metrics, Inc., 20863
Stevens Creek Blvd, Cupertino, California 95014, United States
| | - Michelle Busch
- Sanofi, 1 The Mountain Rd, Framingham, Massachusetts 01701, United States
| | - Anders Lund
- Sanofi, 1 The Mountain Rd, Framingham, Massachusetts 01701, United States
| | - Martha Stapels
- Sanofi, 1 The Mountain Rd, Framingham, Massachusetts 01701, United States
| | - Xu Guo
- SCIEX, 71 Four Valley Drive, Concord, ON L4K
4V8, Canada
| | | | | | - Sean McCarthy
- SCIEX, 500 Old Connecticut Path, Framingham, Massachusetts 01701, United States
| | - John Kim
- Teva, 145 Brandywine Pkwy, West Chester, Pennsylvania 19380, United States
| | - Jing Zhen
- Teva, 145 Brandywine Pkwy, West Chester, Pennsylvania 19380, United States
| | - Ying Zhou
- Teva, 145 Brandywine Pkwy, West Chester, Pennsylvania 19380, United States
| | - Sarah Rogstad
- U.S. Food
and Drug Administration, 10903 New Hampshire Ave, Silver Spring, Maryland 20993, United States
| | - Xiaoshi Wang
- U.S. Food
and Drug Administration, 10903 New Hampshire Ave, Silver Spring, Maryland 20993, United States
| | - Jing Fang
- Waters, 34 Maple St, Milford, Massachusetts 01757, United States
| | - Weibin Chen
- Waters, 34 Maple St, Milford, Massachusetts 01757, United States
| | - Ying Qing Yu
- Waters, 34 Maple St, Milford, Massachusetts 01757, United States
| | | | - Rebecca Scott
- Zoetis, 333 Portage St, Kalamazoo, Michigan 49007, United
States
| | - Hua Yuan
- Zoetis, 333 Portage St, Kalamazoo, Michigan 49007, United
States
| |
Collapse
|
14
|
Pike A, McKinley C, Forrest B, Scott R, Charlton E, Scott E, Zhakata T, Harland M, Clarke D, Davies JR, Toogood A, Houghton N, Youngs N, Barnfield C, Richards S, Payne D, Arnold L, Munir T, Muus P, Griffin M, Kelly RJ, Hillmen P, Newton D. COVID-19 vaccination antibody responses in patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria. Lancet Haematol 2022; 9:e553-e556. [PMID: 35780797 PMCID: PMC9246481 DOI: 10.1016/s2352-3026(22)00183-1] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2022] [Revised: 05/26/2022] [Accepted: 05/30/2022] [Indexed: 12/26/2022]
Affiliation(s)
- Alexandra Pike
- Division of Haematology and Immunology, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, LS9 7TF, UK; Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Claire McKinley
- Division of Haematology and Immunology, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, LS9 7TF, UK
| | - Briony Forrest
- Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Rebecca Scott
- Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Emily Charlton
- Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Emma Scott
- Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Tapiwa Zhakata
- Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Mark Harland
- Division of Haematology and Immunology, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, LS9 7TF, UK
| | - Deborah Clarke
- Division of Haematology and Immunology, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, LS9 7TF, UK
| | - John R Davies
- Leeds Institute of Data Analytics, University of Leeds, Leeds, LS9 7TF, UK
| | - Aurora Toogood
- Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Nicola Houghton
- Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Nora Youngs
- Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | | | - Stephen Richards
- Division of Haematology and Immunology, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, LS9 7TF, UK
| | - Daniel Payne
- Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Louise Arnold
- Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Tahla Munir
- Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Petra Muus
- Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Morag Griffin
- Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Richard J Kelly
- Division of Haematology and Immunology, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, LS9 7TF, UK; Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Peter Hillmen
- Division of Haematology and Immunology, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, LS9 7TF, UK; Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Darren Newton
- Division of Haematology and Immunology, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, LS9 7TF, UK.
| |
Collapse
|
15
|
González Martín R, Palomar A, Zuckerman C, Whitehead C, Quiñonero A, Scott R, Domínguez F. P-670 Phytoestrogen concentration in women’s urine and follicular fluid are associated with better IVF outcomes in euploid single embryo transfer cycles. Hum Reprod 2022. [DOI: 10.1093/humrep/deac107.619] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Study question
What is phytoestrogen exposure impact on the reproductive outcomes of women undergoing IVF treatment?
Summary answer
Increased urinary and follicular fluid phytoestrogen concentration were associated with better IVF outcomes.
What is known already
The impact and safety of phytoestrogens, plant-derived isoflavones with estrogenic activity predominantly present in soy, on female reproductive health and on IVF outcomes continues to be hotly debated. Numerous studies suggest healthy benefits of phytoestrogen consumption: protection against reprotoxic substances, reductions in breast and other cancers, fibroids, menopausal symptoms, cardiovascular disease, inflammation, and metabolic syndrome and obesity. However, many studies suggest a harmful effect due to the endocrine-disruptor properties of phytoestrogens in both male and female reproductive tissues. Its impact on IVF treatments success is still understudied.
Study design, size, duration
60 women attending IVI-RMA New Jersey undergoing IVF with single-embryo transfer (SET) of euploid good-quality blastocyst after PGT analysis were recruited. Patients underwent PGT-SET cycles following standard protocols. Concentrations of two phytoestrogens (daidzein and genistein) were measured in follicular fluid (FF) and urine collected at oocyte pick-up (UOP) and urine collected at transfer day (UT). These measurements were correlated with IVF clinical outcomes.
Participants/materials, setting, methods
Participants were aged 18-42 years old 18.5-29.9 kg/m2 BMI. Measure of both phytoestrogens’ concentration in follicular fluid and urine samples collected at two different time-points was performed by UPLC-MSMS, with internal standards. Urine phytoestrogen concentrations were normalized by creatinine, measured by Jaffe reaction. Generalized linear models were employed to explore IVF outcomes association, estimated as percentile 20th to 80th increase (95% confidence intervals), among log-transformed phytoestrogen concentration. Both unadjusted and age-BMI-adjusted models were applied.
Main results and the role of chance
In fully adjusted models, higher sum of phytoestrogen concentration in follicular fluid (FF) were significantly associated with higher estradiol at hCG [1.31 (1.04, 1.65), p = 0.023]; whereas the sum of creatinine-corrected phytoestrogens measured in oocyte pick-up urine (UOP) were significantly associated with higher MII oocytes number [1.29 (1.07, 1.56), p = 0.008] and higher fertilized oocytes number [1.34 (1.10, 1.64), p = 0. 004]. Regarding clinical IVF outcomes, in fully adjusted models a higher follicular fluid and oocyte pick-up urine phytoestrogens concentration was significantly associated with higher implantation ratio [8.60 (1.09, 68.03), p = 0. 023] for FF, and [5.01 (0.96, 26.21), p = 0. 05] for UOP; higher clinical pregnancies ratio [5.58 (1.31, 23.73), p = 0.017] for FF, and [3.25 (0.99, 10.63), p = 0.045] for UOP; higher live newborns ratio [5.58 (1.31, 23.73), p = 0.017] for FF, and [3.25 (0.99, 10.63), p = 0.045] for UOP; and higher number of women with live newborns among those who started treatment [4.29 (1.28, 14.38), p = 0.016] for FF, and [2.83 (0.99, 8.07), p = 0.047] for UOP.
Limitations, reasons for caution
Further studies are needed to confirm this association in other populations, including the measurement of other estrogenic isoflavones and its metabolites.
Wider implications of the findings
This is the first work evaluating the association between phytoestrogens concentrations in different biofluids and IVF reproductive outcomes. Our results, using an euploid SET, suggest a beneficial effect of phytoestrogen consumption in women undergoing IVF treatment, further studies are needed to assess the benefit of phytoestrogen supplementation on IVF outcomes.
Trial registration number
-
Collapse
Affiliation(s)
| | - A Palomar
- IVI Foundation-RMA Global , Research, Valencia, Spain
- IIS La Fe, Reproductive Medicine , Valencia, Spain
| | - C Zuckerman
- IVI/RMA New Jersey, Center for Clinical Research , Basking Ridge, U.S.A
| | - C Whitehead
- IVI/RMA New Jersey, Center for Clinical Research , Basking Ridge, U.S.A
| | - A Quiñonero
- IVI Foundation-RMA Global , Research, Valencia, Spain
| | - R Scott
- IVI/RMA New Jersey, Center for Clinical Research , Basking Ridge, U.S.A
- Thomas Jefferson University, Sidney Kimmel College of Medicine , Philadelphia, U.S.A
| | - F Domínguez
- IVI Foundation-RMA Global , Research, Valencia, Spain
- IIS La Fe, Reproductive Medicine , Valencia, Spain
| |
Collapse
|
16
|
Scott R, Mora M, Saloio J, Cushman J, Sakurada R, Kumar K, Lipkens B, Tostoes R. Process Development and Manufacturing: THE EKKO™ AND EKKO™ SELECT: ACOUSTIC-BASED CLOSED AND AUTOMATED SYSTEMS FOR CELL AND GENE THERAPY CGMP MANUFACTURING. Cytotherapy 2022. [DOI: 10.1016/s1465-3249(22)00474-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
17
|
Kettemer LE, Biastoch A, Wagner P, Coombs EJ, Penrose R, Scott R. Oceanic drivers of juvenile sea turtle strandings in the UK. ENDANGER SPECIES RES 2022. [DOI: 10.3354/esr01184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
18
|
Scott R, Oliver N, Thomas M, Agha-Jaffar R. Pregnancy and contraception in women with Pre-Gestational diabetes in secondary Care- A questionnaire study. Diabetes Res Clin Pract 2021; 182:109124. [PMID: 34740741 DOI: 10.1016/j.diabres.2021.109124] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/20/2021] [Revised: 10/10/2021] [Accepted: 10/31/2021] [Indexed: 11/24/2022]
Abstract
AIMS To establish the knowledge of women with pre-gestational diabetes about of the risks of diabetes in pregnancy, and investigate their pregnancy plans, contraceptive choices, and preparedness for pregnancy. METHODS Women of reproductive age attending diabetes clinics across a single busy metropolitan NHS Trust were invited to fill in a questionnaire about pregnancy and contraception. The electronic health records of those women were also reviewed. RESULTS Ninety-six women completed the questionnaire. The majority of respondents (94%) had Type 1 Diabetes. Only 3% of women met the criteria of 'prepared for pregnancy'. Low efficacy contraception was used by 32% of women. Most women were only aware of a few risks to the mother and fetus in pregnancy, though the majority of women were aware of the importance of good glycaemic control before pregnancy. Previous pregnancies, or attendance at pre-conception counselling, did not improve participant knowledge. CONCLUSIONS Many women with diabetes of reproductive age are poorly prepared for pregnancy, but many are also using less effective contraceptive methods. These areas should be addressed if the poor pregnancy outcome in women with diabetes are to be improved, possibly through the development of an evidenced-based structured education course to target pre-conception and contraception.
Collapse
Affiliation(s)
- R Scott
- Department of Diabetes & Endocrinology, St Mary's Hospital, Imperial College Healthcare NHS Trust, Praed Street, London W2 1NY, England; Faculty of Medicine, 10(th) Floor Commonwealth Building, Hammersmith Hospital Campus, Imperial College London, Du Cane Road, London W12 0NN, England.
| | - N Oliver
- Department of Diabetes & Endocrinology, St Mary's Hospital, Imperial College Healthcare NHS Trust, Praed Street, London W2 1NY, England; Faculty of Medicine, 10(th) Floor Commonwealth Building, Hammersmith Hospital Campus, Imperial College London, Du Cane Road, London W12 0NN, England.
| | - M Thomas
- Faculty of Medicine, 10(th) Floor Commonwealth Building, Hammersmith Hospital Campus, Imperial College London, Du Cane Road, London W12 0NN, England
| | - R Agha-Jaffar
- Department of Diabetes & Endocrinology, St Mary's Hospital, Imperial College Healthcare NHS Trust, Praed Street, London W2 1NY, England; Faculty of Medicine, 10(th) Floor Commonwealth Building, Hammersmith Hospital Campus, Imperial College London, Du Cane Road, London W12 0NN, England.
| |
Collapse
|
19
|
Affiliation(s)
- Carolyn Stephens
- UCL Bartlett Development Planning Unit, London School of Hygiene and Tropical Medicine, London, UK
| | - Nicolas Mays
- Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK
| | - Rita Issa
- Institute of Global Health, UCL, London, UK
| | | | | |
Collapse
|
20
|
Scott R, Parker H, Mccartney S, Harrow P, Williams D, Giles I. Outcomes following biosimilar TNF inhibitors use for inflammatory-mediated immune disorders in pregnancy. Obstet Med 2021; 15:104-107. [PMID: 35845229 PMCID: PMC9277732 DOI: 10.1177/1753495x211028779] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2021] [Revised: 05/15/2021] [Accepted: 06/09/2021] [Indexed: 12/03/2022] Open
Abstract
Background Biosimilar tumour necrosis factor inhibitors (TNFi) are increasingly used to
treat inflammatory immune-mediated disorders as they cost less than the
originator biologic drug. More women are therefore becoming pregnant on
biosimilar TNFi. This is the first paper to explore the safety and efficacy
of biosimilar therapies in pregnancy. Methods A retrospective review of clinical data reviewed pregnancy outcomes and
inflammatory disease activity in 18 pregnancies where the mother was using a
biosimilar TNFi at conception. Results Biosimilar therapy was not associated with congenital abnormalities, preterm
birth or other adverse pregnancy outcomes. Stopping biosimilar TNFi in
pregnancy was associated with childbirth at an earlier gestation, as well as
a flare of inflammatory disease in pregnancy or post-partum. Conclusions Women and clinicians should feel confident in using biosimilar TNFi in early
pregnancy, and continuing them through pregnancy to prevent flares in late
pregnancy or the early post-partum.
Collapse
Affiliation(s)
- R Scott
- Department of Obstetrics, University College London Hospital NHS Foundation Trust, London, UK
| | - H Parker
- Department of Gastroenterology, University College London Hospital NHS Foundation Trust, London, UK
| | - S Mccartney
- Department of Gastroenterology, University College London Hospital NHS Foundation Trust, London, UK
| | - P Harrow
- Department of Gastroenterology, University College London Hospital NHS Foundation Trust, London, UK
| | - D Williams
- Department of Obstetrics, University College London Hospital NHS Foundation Trust, London, UK
- The Institute for Women’s Health, University College London, London, UK
| | - I Giles
- Department for Rheumatology, University College London Hospital NHS Foundation Trust, London, UK
- Centre for Rheumatology, University College London, University College London Hospitals NHS Foundation Trust, London, UK
| |
Collapse
|
21
|
Doyle J, McCain S, Scott R, Love M. AXIOS STENTS: TRANSFORMING THE MANAGEMENT OF PANCREATIC FLUID COLLECTIONS. Ulster Med J 2021; 90:192. [PMID: 34815600 PMCID: PMC8581693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Affiliation(s)
- J Doyle
- Belfast Health and Social Care Trust, Lisburn Road, Belfast, BT9 7AD
| | - S McCain
- Belfast Health and Social Care Trust, Lisburn Road, Belfast, BT9 7AD
| | - R Scott
- Belfast Health and Social Care Trust, Lisburn Road, Belfast, BT9 7AD
| | - M Love
- Belfast Health and Social Care Trust, Lisburn Road, Belfast, BT9 7AD
| |
Collapse
|
22
|
Grey A, Scott R, Shah B, Acher P, Liyanage S, Pavlou M, Omar R, Chinegwundoh F, Patki P, Campbell D, Shah TT, Hamid S, Brew-Graves C, Arumainayagam N, Chapman A, Eldred-Evans D, Freeman A, Winkler M, Emberton M, Ahmed HU. The CADMUS trial: A paired cohort, blinded study comparing multiparametric ultrasound targeted biopsies with multiparametric MRI targeted biopsies in the detection of clinically significant prostate cancer. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.5008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5008 Background: Multiparametric MRI (mpMRI) of the prostate followed by targeted biopsy is recommended in men at risk of prostate cancer. Dissemination of this pathway may be limited by cost, variable scan and reporting quality, and contraindicated in the presence of metallic implants and claustrophobia. Multi-parametric ultrasound (mpUSS) is a point of care test with low cost that combines b-mode, colour Doppler, elastography and contrast enhancement. CADMUS compared the diagnostic performance of mpUSS to mpMRI. Methods: CADMUS recruited 370 patients from seven sites to a prospective, multicentre, paired-cohort trial (ISRCTN 38541912). Ethics committee approval was obtained. Patients underwent both mpUSS and mpMRI independently, each with a positive test defined as a Likert score of >3. Those with either a positive mpUSS or mpMRI, or both, were advised to undergo targeted biopsies. Reporting of each scan was carried out blind to the other and prior to biopsy; patients advised for biopsy were blinded to which test was positive. The order of mpUSS and mpMRI targeting was randomised. Primary outcomes were proportion of positive tests and detection of clinically significant cancer (csPCa) defined as Gleason >4+3 of any length and/or maximum cancer core length of >6mm of any grade [PROMIS definition1]. Results: 306 completed both mpUSS and mpMRI. Agreement in lesion detection between mpUSS and mpMRI was 73.2% (kappa 0.06, p = 0.14). 257 with positive results on mpUSS, mpMRI or both had targeted biopsies. Agreement on detection of csPCa was 91.1% (expected 59.8%, kappa 0.78, p < 0.01). Overall, mpUSS detected 4.3% fewer csPCa than mpMRI (95% CI = [-8.3%, -1.5%]; p = 0.042 [Bonferroni correction]). mpUSS detected 7.2% (6/83) csPCa missed by mpMRI; mpMRI detected 20.5% (17/83) csPCa that mpUSS missed. At a less stringent definition of significant cancer, Gleason grade >3+4 of any length (definition 3), agreement was 89.1% (expected 55.6%, kappa 0.75, p < 0.01) mpUSS detected 5.4% fewer definition 3 cancers than mpMRI overall. mpUSS detected 7% (7/99) definition 3 cancers that mpMRI missed; mpMRI detected 21% (21/99) definition 3 cancers that mpUSS missed. Conclusions: The CADMUS trial shows mpUSS has a diagnostic performance approaching that of mpMRI and significant cancer detection is improved by the use of both scans over mpMRI alone. Clinical trial information: 38541912. [Table: see text]
Collapse
Affiliation(s)
| | | | - Bina Shah
- Surgical and Interventional Trials Unit, University College London, London, United Kingdom
| | - Peter Acher
- Southend University Hospital, Southend, United Kingdom
| | - Sidath Liyanage
- Department of Radiology, Southend University Hospital, Southend, United Kingdom
| | | | - Rumana Omar
- University College London Medical School, London, United Kingdom
| | | | - Prasad Patki
- Barts and the Royal London Hospitals, London, United Kingdom
| | | | | | - Sami Hamid
- Department of Urology, The Whittington Hospital, London, United Kingdom
| | - Chris Brew-Graves
- Division of Medicine, University College London, London, United Kingdom
| | - Nim Arumainayagam
- Department of Urology, Ashford and St Peters Hospitals, London, United Kingdom
| | - Alex Chapman
- Department of Radiology, Ashford and St Peter's Hospitals, London, United Kingdom
| | | | - Alex Freeman
- University College London, London, United Kingdom
| | - Mathias Winkler
- Imperial College Healthcare NHS Trust, London, United Kingdom
| | | | | | | |
Collapse
|
23
|
Gunner RM, Wilson RP, Holton MD, Scott R, Arkwright A, Fahlman A, Ulrich M, Hopkins P, Duarte C, Eizaguirre C. Activity of loggerhead turtles during the U-shaped dive: insights using angular velocity metrics. ENDANGER SPECIES RES 2021. [DOI: 10.3354/esr01125] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Understanding the behavioural ecology of endangered taxa can inform conservation strategies. The activity budgets of the loggerhead turtle Caretta caretta are still poorly understood because many tracking methods show only horizontal displacement and ignore dives and associated behaviours. However, time-depth recorders have enabled researchers to identify flat, U-shaped dives (or type 1a dives) and these are conventionally labelled as resting dives on the seabed because they involve no vertical displacement of the animal. Video- and acceleration-based studies have demonstrated this is not always true. Focusing on sea turtles nesting on the Cabo Verde archipelago, we describe a new metric derived from magnetometer data, absolute angular velocity, that integrates indices of angular rotation in the horizontal plane to infer activity. Using this metric, we evaluated the variation in putative resting behaviours during the bottom phase of type 1a dives for 5 individuals over 13 to 17 d at sea during a single inter-nesting interval (over 75 turtle d in total). We defined absolute resting within the bottom phase of type 1a dives as periods with no discernible acceleration or angular movement. Whilst absolute resting constituted a significant proportion of each turtle’s time budget for this 1a dive type, turtles allocated 16-38% of their bottom time to activity, with many dives being episodic, comprised of intermittent bouts of rest and rotational activity. This implies that previously considered resting behaviours are complex and need to be accounted for in energy budgets, particularly since energy budgets may impact conservation strategies.
Collapse
Affiliation(s)
- RM Gunner
- Swansea Lab for Animal Movement, Biosciences, College of Science, Swansea University, Swansea SA2 8PP, UK
| | - RP Wilson
- Swansea Lab for Animal Movement, Biosciences, College of Science, Swansea University, Swansea SA2 8PP, UK
| | - MD Holton
- Swansea Lab for Animal Movement, Biosciences, College of Science, Swansea University, Swansea SA2 8PP, UK
| | - R Scott
- GEOMAR Helmholtz Centre for Ocean Research, Kiel, Düsternbrooker Weg 20, 24105 Kiel, Germany
- Natural Environmental Research Council, Polaris House, North Star Avenue, Swindon SN2 1FL, UK
| | - A Arkwright
- Swansea Lab for Animal Movement, Biosciences, College of Science, Swansea University, Swansea SA2 8PP, UK
- L’Oceanogràfic, Ciutat de les Arts i de les Ciències, Carrer d’Eduardo Primo Yúfera, 1B, 46013 Valencia, Spain
| | - A Fahlman
- L’Oceanogràfic, Ciutat de les Arts i de les Ciències, Carrer d’Eduardo Primo Yúfera, 1B, 46013 Valencia, Spain
| | - M Ulrich
- Institutionen för fysik kemi och biologi (IFM), Linköping Universitet, Olaus Magnus väg, 583 30 Linköping, Sweden
| | - P Hopkins
- Swansea Lab for Animal Movement, Biosciences, College of Science, Swansea University, Swansea SA2 8PP, UK
| | - C Duarte
- Red Sea Research Centre, King Abdullah University of Science and Technology (KAUST), Thuwal 23955, Saudi Arabia
| | - C Eizaguirre
- School of Biological and Chemical Sciences, Queen Mary University of London, London E35SA, UK
| |
Collapse
|
24
|
Scott R, Cornish E, Williams D. Alemtuzumab-Induced Hypothyroidism Presenting in Pregnancy - the First 2 Reported Cases. J Endocr Soc 2021. [DOI: 10.1210/jendso/bvab048.1877] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Abstract
Introduction: Alemtuzumab is a monoclonal antibody that improves outcomes in patients with relapsing-remitting multiple sclerosis. It binds to CD52 and causes a profound depletion of B and T lymphocytes. Autoreactive T cells often form as the immune system repopulates, causing autoimmune thyroid dysfunction in approximately 35% of patients. Alemtuzumab has been associated with new-onset hyperthyroidism during a subsequent pregnancy. Here, we present the first two cases of alemtuzumab-induced hypothyroidism diagnosed in pregnancy. Diagnosing and treating de novo thyroid dysfunction in pregnancy is essential for optimal fetal development and maternal wellbeing.
Clinical Cases: Case A: A 28-year-old woman conceived 26 months after alemtuzumab therapy. Prior to pregnancy, routine TFTs showed euthyroidism. At 17 weeks’ gestation she presented with fatigue, and blood tests confirmed overt hypothyroidism (TSH >100mIU/L (<4IU/L), fT4 3.7pmol/L (9-15pmol/L)). TRABs were positive. She was treated with levothyroxine, and TFTs normalised by 38 weeks’ gestation. Serial fetal ultrasounds showed constant growth velocity and no fetal goitre or tachycardia. The baby was born at term with birthweight on the 30th centile. On day 5 postpartum, the baby had a normal TSH of 3.1mIU/l (0.27-4.20mIU/l) but elevated fT4 of 31.5pmol/L (12-22pmol/L), which fell spontaneously to 22.0pmol/L by day 11.
Case B: A 37-year-old woman conceived 19 months after alemtuzumab therapy. Prior to pregnancy, routine TFTs had been within normal limits. However at 5 weeks’ gestation, blood tests showed overt hypothyroidism (TSH 47.9mIU/L (<4iU/L)), fT4 8.8pmol/l (10-16pmol/L)). Her only symptom was fatigue. TRABs were elevated. She was treated with levothyroxine, and TFTs normalised by 16 weeks’ gestation. Serial fetal ultrasound scans showed constant growth velocity and no fetal goitre or tachycardia. The baby was born at term with birthweight on the 25th centile. On day 1 postpartum, the baby had a normal fT4 (16.5pmol/l)but elevated TSH 13.02mIU/L, which normalised spontaneously by day 11 tp 1/64mIU/l.
Conclusion: To optimise pregnancy outcomes, we recommend that women previously treated with alemtuzumab should be screened monthly for thyroid dysfunction during a subsequent pregnancy. The neonatal team should be alert to transient neonatal thyroid dysfunction, which, like spontaneous alloimmune neonatal thyroid disease, appears to settle spontaneously. References: Garrahy et al. JCEM, 2019, 104 (9), 3624-3625Thakar et al. JCEM 2019, 104 (9), 3626-3627
Collapse
Affiliation(s)
- Rebecca Scott
- University College London Hospital NHS Foundation Trust, London, United Kingdom
| | - Emily Cornish
- University College London Hospital NHS Foundation Trust, London, United Kingdom
| | - Daivd Williams
- University College London Hospital NHS Foundation Trust, London, United Kingdom
| |
Collapse
|
25
|
Frampton D, Rampling T, Cross A, Bailey H, Heaney J, Byott M, Scott R, Sconza R, Price J, Margaritis M, Bergstrom M, Spyer MJ, Miralhes PB, Grant P, Kirk S, Valerio C, Mangera Z, Prabhahar T, Moreno-Cuesta J, Arulkumaran N, Singer M, Shin GY, Sanchez E, Paraskevopoulou SM, Pillay D, McKendry RA, Mirfenderesky M, Houlihan CF, Nastouli E. Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study. Lancet Infect Dis 2021; 21:1246-1256. [PMID: 33857406 PMCID: PMC8041359 DOI: 10.1016/s1473-3099(21)00170-5] [Citation(s) in RCA: 265] [Impact Index Per Article: 88.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/06/2021] [Revised: 03/05/2021] [Accepted: 03/08/2021] [Indexed: 01/14/2023]
Abstract
Background Emergence of variants with specific mutations in key epitopes in the spike protein of SARS-CoV-2 raises concerns pertinent to mass vaccination campaigns and use of monoclonal antibodies. We aimed to describe the emergence of the B.1.1.7 variant of concern (VOC), including virological characteristics and clinical severity in contemporaneous patients with and without the variant. Methods In this cohort study, samples positive for SARS-CoV-2 on PCR that were collected from Nov 9, 2020, for patients acutely admitted to one of two hospitals on or before Dec 20, 2020, in London, UK, were sequenced and analysed for the presence of VOC-defining mutations. We fitted Poisson regression models to investigate the association between B.1.1.7 infection and severe disease (defined as point 6 or higher on the WHO ordinal scale within 14 days of symptoms or positive test) and death within 28 days of a positive test and did supplementary genomic analyses in a cohort of chronically shedding patients and in a cohort of remdesivir-treated patients. Viral load was compared by proxy, using PCR cycle threshold values and sequencing read depths. Findings Of 496 patients with samples positive for SARS-CoV-2 on PCR and who met inclusion criteria, 341 had samples that could be sequenced. 198 (58%) of 341 had B.1.1.7 infection and 143 (42%) had non-B.1.1.7 infection. We found no evidence of an association between severe disease and death and lineage (B.1.1.7 vs non-B.1.1.7) in unadjusted analyses (prevalence ratio [PR] 0·97 [95% CI 0·72–1·31]), or in analyses adjusted for hospital, sex, age, comorbidities, and ethnicity (adjusted PR 1·02 [0·76–1·38]). We detected no B.1.1.7 VOC-defining mutations in 123 chronically shedding immunocompromised patients or in 32 remdesivir-treated patients. Viral load by proxy was higher in B.1.1.7 samples than in non-B.1.1.7 samples, as measured by cycle threshold value (mean 28·8 [SD 4·7] vs 32·0 [4·8]; p=0·0085) and genomic read depth (1280 [1004] vs 831 [682]; p=0·0011). Interpretation Emerging evidence exists of increased transmissibility of B.1.1.7, and we found increased virus load by proxy for B.1.1.7 in our data. We did not identify an association of the variant with severe disease in this hospitalised cohort. Funding University College London Hospitals NHS Trust, University College London/University College London Hospitals NIHR Biomedical Research Centre, Engineering and Physical Sciences Research Council.
Collapse
Affiliation(s)
- Dan Frampton
- Division of Infection and Immunity, University College London, London, UK; Advanced Pathogen Diagnostics Unit, University College London Hospitals NHS Foundation Trust, London, UK; The Francis Crick Institute, London, UK
| | - Tommy Rampling
- Department of Clinical Virology, University College London Hospitals NHS Foundation Trust, London, UK
| | - Aidan Cross
- North Middlesex University Hospital NHS Trust, London, UK
| | - Heather Bailey
- Institute for Global Health, University College London, London, UK
| | - Judith Heaney
- Advanced Pathogen Diagnostics Unit, University College London Hospitals NHS Foundation Trust, London, UK; The Francis Crick Institute, London, UK
| | - Matthew Byott
- Advanced Pathogen Diagnostics Unit, University College London Hospitals NHS Foundation Trust, London, UK; The Francis Crick Institute, London, UK
| | - Rebecca Scott
- North Middlesex University Hospital NHS Trust, London, UK
| | - Rebecca Sconza
- Great Ormond Street Institute of Child Health, University College London, London, UK
| | - Joseph Price
- North Middlesex University Hospital NHS Trust, London, UK
| | - Marios Margaritis
- Department of Clinical Virology, University College London Hospitals NHS Foundation Trust, London, UK; London School of Hygiene & Tropical Medicine, London, UK
| | - Malin Bergstrom
- Department of Clinical Virology, University College London Hospitals NHS Foundation Trust, London, UK
| | - Moira J Spyer
- Great Ormond Street Institute of Child Health, University College London, London, UK; Advanced Pathogen Diagnostics Unit, University College London Hospitals NHS Foundation Trust, London, UK; The Francis Crick Institute, London, UK
| | - Patricia B Miralhes
- Department of Clinical Virology, University College London Hospitals NHS Foundation Trust, London, UK
| | - Paul Grant
- Advanced Pathogen Diagnostics Unit, University College London Hospitals NHS Foundation Trust, London, UK; North Middlesex University Hospital NHS Trust, London, UK
| | | | - Chris Valerio
- North Middlesex University Hospital NHS Trust, London, UK
| | - Zaheer Mangera
- Division of Infection and Immunity, University College London, London, UK
| | | | | | - Nish Arulkumaran
- Bloomsbury Institute of Intensive Care Medicine, University College London, London, UK
| | - Mervyn Singer
- Bloomsbury Institute of Intensive Care Medicine, University College London, London, UK
| | - Gee Yen Shin
- Department of Clinical Virology, University College London Hospitals NHS Foundation Trust, London, UK
| | - Emilie Sanchez
- Department of Clinical Virology, University College London Hospitals NHS Foundation Trust, London, UK
| | | | - Deenan Pillay
- Division of Infection and Immunity, University College London, London, UK
| | - Rachel A McKendry
- London Centre for Nanotechnology, University College London, London, UK; Division of Medicine, University College London, London, UK
| | | | - Catherine F Houlihan
- Division of Infection and Immunity, University College London, London, UK; Department of Clinical Virology, University College London Hospitals NHS Foundation Trust, London, UK
| | - Eleni Nastouli
- Great Ormond Street Institute of Child Health, University College London, London, UK; Advanced Pathogen Diagnostics Unit, University College London Hospitals NHS Foundation Trust, London, UK; Department of Clinical Virology, University College London Hospitals NHS Foundation Trust, London, UK; The Francis Crick Institute, London, UK.
| |
Collapse
|
26
|
Mouchahoir T, Schiel JE, Rogers R, Heckert A, Place BJ, Ammerman A, Li X, Robinson T, Schmidt B, Chumsae CM, Li X, Manuilov AV, Yan B, Staples GO, Ren D, Veach AJ, Wang D, Yared W, Sosic Z, Wang Y, Zang L, Leone AM, Liu P, Ludwig R, Tao L, Wu W, Cansizoglu A, Hanneman A, Adams GW, Perdivara I, Walker H, Wilson M, Brandenburg A, DeGraan-Weber N, Gotta S, Shambaugh J, Alvarez M, Yu XC, Cao L, Shao C, Mahan A, Nanda H, Nields K, Nightlinger N, Barysz HM, Jahn M, Niu B, Wang J, Leo G, Sepe N, Liu YH, Patel BA, Richardson D, Wang Y, Tizabi D, Borisov OV, Lu Y, Maynard EL, Gruhler A, Haselmann KF, Krogh TN, Sönksen CP, Letarte S, Shen S, Boggio K, Johnson K, Ni W, Patel H, Ripley D, Rouse JC, Zhang Y, Daniels C, Dawdy A, Friese O, Powers TW, Sperry JB, Woods J, Carlson E, Sen KI, Skilton SJ, Busch M, Lund A, Stapels M, Guo X, Heidelberger S, Kaluarachchi H, McCarthy S, Kim J, Zhen J, Zhou Y, Rogstad S, Wang X, Fang J, Chen W, Yu YQ, Hoogerheide JG, Scott R, Yuan H. New Peak Detection Performance Metrics from the MAM Consortium Interlaboratory Study. J Am Soc Mass Spectrom 2021; 32:913-928. [PMID: 33710905 DOI: 10.1021/jasms.0c00415] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/09/2023]
Abstract
The Multi-Attribute Method (MAM) Consortium was initially formed as a venue to harmonize best practices, share experiences, and generate innovative methodologies to facilitate widespread integration of the MAM platform, which is an emerging ultra-high-performance liquid chromatography-mass spectrometry application. Successful implementation of MAM as a purity-indicating assay requires new peak detection (NPD) of potential process- and/or product-related impurities. The NPD interlaboratory study described herein was carried out by the MAM Consortium to report on the industry-wide performance of NPD using predigested samples of the NISTmAb Reference Material 8671. Results from 28 participating laboratories show that the NPD parameters being utilized across the industry are representative of high-resolution MS performance capabilities. Certain elements of NPD, including common sources of variability in the number of new peaks detected, that are critical to the performance of the purity function of MAM were identified in this study and are reported here as a means to further refine the methodology and accelerate adoption into manufacturer-specific protein therapeutic product life cycles.
Collapse
Affiliation(s)
- Trina Mouchahoir
- National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, Maryland 20899, United States
- Institute for Bioscience and Biotechnology Research, 9600 Gudelsky Drive, Rockville, Maryland 20850, United States
| | - John E Schiel
- National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, Maryland 20899, United States
- Institute for Bioscience and Biotechnology Research, 9600 Gudelsky Drive, Rockville, Maryland 20850, United States
| | - Rich Rogers
- Just - Evotech Biologics, 401 Terry Avenue N, Seattle, Washington 98109, United States
| | - Alan Heckert
- National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, Maryland 20899, United States
| | - Benjamin J Place
- National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, Maryland 20899, United States
| | - Aaron Ammerman
- AbbVie, 1500 Seaport Boulevard, Redwood City, California 94063, United States
| | - Xiaoxiao Li
- AbbVie, 1500 Seaport Boulevard, Redwood City, California 94063, United States
| | - Tom Robinson
- AbbVie, 1500 Seaport Boulevard, Redwood City, California 94063, United States
| | - Brian Schmidt
- AbbVie, 1500 Seaport Boulevard, Redwood City, California 94063, United States
| | - Chris M Chumsae
- AbbVie, 100 Research Drive, Worcester, Massachusetts 01605, United States
| | - Xinbi Li
- AbbVie, 100 Research Drive, Worcester, Massachusetts 01605, United States
| | - Anton V Manuilov
- AbbVie, 100 Research Drive, Worcester, Massachusetts 01605, United States
| | - Bo Yan
- AbbVie, 100 Research Drive, Worcester, Massachusetts 01605, United States
| | - Gregory O Staples
- Agilent Technologies, 5301 Stevens Creek Boulevard, Santa Clara, California 95008, United States
| | - Da Ren
- Amgen, One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Alexander J Veach
- Amgen, One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Dongdong Wang
- BioAnalytix, 790 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Wael Yared
- BioAnalytix, 790 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Zoran Sosic
- Biogen, 125 Broadway, Cambridge, Massachusetts 02142, United States
| | - Yan Wang
- Biogen, 125 Broadway, Cambridge, Massachusetts 02142, United States
| | - Li Zang
- Biogen, 125 Broadway, Cambridge, Massachusetts 02142, United States
| | - Anthony M Leone
- Bristol-Myers Squibb, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States
| | - Peiran Liu
- Bristol-Myers Squibb, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States
| | - Richard Ludwig
- Bristol-Myers Squibb, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States
| | - Li Tao
- Bristol-Myers Squibb, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States
| | - Wei Wu
- Bristol-Myers Squibb, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States
| | - Ahmet Cansizoglu
- Charles River Laboratories, 8 Henshaw Street, Shrewsbury, Massachusetts 01801, United States
| | - Andrew Hanneman
- Charles River Laboratories, 8 Henshaw Street, Shrewsbury, Massachusetts 01801, United States
| | - Greg W Adams
- FUJIFILM Diosynth Biotechnologies, 101 J. Morris Commons Lane, Morrisville, North Carolina 27560, United States
| | - Irina Perdivara
- FUJIFILM Diosynth Biotechnologies, 101 J. Morris Commons Lane, Morrisville, North Carolina 27560, United States
| | - Hunter Walker
- FUJIFILM Diosynth Biotechnologies, 101 J. Morris Commons Lane, Morrisville, North Carolina 27560, United States
| | - Margo Wilson
- FUJIFILM Diosynth Biotechnologies, 101 J. Morris Commons Lane, Morrisville, North Carolina 27560, United States
| | | | - Nick DeGraan-Weber
- Genedata, 750 Marrett Road, One Cranberry Hill, Lexington, Massachusetts 02421, United States
| | - Stefano Gotta
- Genedata, Margarethenstrasse 38, Basel 4053, Switzerland
| | - Joe Shambaugh
- Genedata, 750 Marrett Road, One Cranberry Hill, Lexington, Massachusetts 02421, United States
| | - Melissa Alvarez
- Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - X Christopher Yu
- Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - Li Cao
- GSK, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - Chun Shao
- GSK, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - Andrew Mahan
- Janssen, 1400 McKean Road, Springhouse, Pennsylvania 19477, United States
| | - Hirsh Nanda
- Janssen, 1400 McKean Road, Springhouse, Pennsylvania 19477, United States
| | - Kristen Nields
- Janssen, 1400 McKean Road, Springhouse, Pennsylvania 19477, United States
| | - Nancy Nightlinger
- Just - Evotech Biologics, 401 Terry Avenue N, Seattle, Washington 98109, United States
| | | | - Michael Jahn
- Lonza, Hochbergerstrasse 60 A, Basel 4057, Switzerland
| | - Ben Niu
- AstraZeneca, One MedImmune Way, Gaithersburg, Maryland 20878, United States
| | - Jihong Wang
- AstraZeneca, One MedImmune Way, Gaithersburg, Maryland 20878, United States
| | - Gabriella Leo
- EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, Via Luigi Einaudi 11, Guidonia Montecelio (Roma) 00012, Italy
| | - Nunzio Sepe
- EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, Via Luigi Einaudi 11, Guidonia Montecelio (Roma) 00012, Italy
| | - Yan-Hui Liu
- Merck & Co., Inc., 2000 Galloping Hill Roa, Kenilworth, New Jersey 07033, United States
| | - Bhumit A Patel
- Merck & Co., Inc., 2000 Galloping Hill Roa, Kenilworth, New Jersey 07033, United States
| | - Douglas Richardson
- Merck & Co., Inc., 2000 Galloping Hill Roa, Kenilworth, New Jersey 07033, United States
| | - Yi Wang
- Merck & Co., Inc., 2000 Galloping Hill Roa, Kenilworth, New Jersey 07033, United States
| | - Daniela Tizabi
- National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, Maryland 20899, United States
- Institute for Bioscience and Biotechnology Research, 9600 Gudelsky Drive, Rockville, Maryland 20850, United States
| | - Oleg V Borisov
- Novavax, Inc., 20 Firstfield Road, Gaithersburg, Maryland 20878, United States
| | - Yali Lu
- Novavax, Inc., 20 Firstfield Road, Gaithersburg, Maryland 20878, United States
| | - Ernest L Maynard
- Novavax, Inc., 20 Firstfield Road, Gaithersburg, Maryland 20878, United States
| | | | | | | | | | - Simon Letarte
- Pfizer, 375 North Field Drive, Lake Forest, Illinois 60045, United States
| | - Sean Shen
- Pfizer, 375 North Field Drive, Lake Forest, Illinois 60045, United States
| | - Kristin Boggio
- Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States
| | - Keith Johnson
- Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States
| | - Wenqin Ni
- Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States
| | - Himakshi Patel
- Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States
| | - David Ripley
- Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States
| | - Jason C Rouse
- Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States
| | - Ying Zhang
- Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States
| | - Carly Daniels
- Pfizer, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, United States
| | - Andrew Dawdy
- Pfizer, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, United States
| | - Olga Friese
- Pfizer, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, United States
| | - Thomas W Powers
- Pfizer, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, United States
| | - Justin B Sperry
- Pfizer, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, United States
| | - Josh Woods
- Pfizer, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, United States
| | - Eric Carlson
- Protein Metrics, Inc., 20863 Stevens Creek Boulevard, Cupertino, California 95014, United States
| | - K Ilker Sen
- Protein Metrics, Inc., 20863 Stevens Creek Boulevard, Cupertino, California 95014, United States
| | - St John Skilton
- Protein Metrics, Inc., 20863 Stevens Creek Boulevard, Cupertino, California 95014, United States
| | - Michelle Busch
- Sanofi, 1 The Mountain Road, Framingham, Massachusetts 01701, United States
| | - Anders Lund
- Sanofi, 1 The Mountain Road, Framingham, Massachusetts 01701, United States
| | - Martha Stapels
- Sanofi, 1 The Mountain Road, Framingham, Massachusetts 01701, United States
| | - Xu Guo
- SCIEX, 71 Four Valley Drive, Concord, ON L4K 4 V8, Canada
| | | | | | - Sean McCarthy
- SCIEX, 500 Old Connecticut Path, Framingham, Massachusetts 01701, United States
| | - John Kim
- Teva, 145 Brandywine Pkwy, West Chester, Pennsylvania 19380, United States
| | - Jing Zhen
- Teva, 145 Brandywine Pkwy, West Chester, Pennsylvania 19380, United States
| | - Ying Zhou
- Teva, 145 Brandywine Pkwy, West Chester, Pennsylvania 19380, United States
| | - Sarah Rogstad
- U.S. Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, Maryland 20993, United States
| | - Xiaoshi Wang
- U.S. Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, Maryland 20993, United States
| | - Jing Fang
- Waters, 34 Maple Street, Milford, Massachusetts 01757, United States
| | - Weibin Chen
- Waters, 34 Maple Street, Milford, Massachusetts 01757, United States
| | - Ying Qing Yu
- Waters, 34 Maple Street, Milford, Massachusetts 01757, United States
| | | | - Rebecca Scott
- Zoetis, 333 Portage Street, Kalamazoo, Michigan 49007, United States
| | - Hua Yuan
- Zoetis, 333 Portage Street, Kalamazoo, Michigan 49007, United States
| |
Collapse
|
27
|
Kosmicki JA, Horowitz JE, Banerjee N, Lanche R, Marcketta A, Maxwell E, Bai X, Sun D, Backman JD, Sharma D, Kang HM, O'Dushlaine C, Yadav A, Mansfield AJ, Li AH, Watanabe K, Gurski L, McCarthy SE, Locke AE, Khalid S, O'Keeffe S, Mbatchou J, Chazara O, Huang Y, Kvikstad E, O'Neill A, Nioi P, Parker MM, Petrovski S, Runz H, Szustakowski JD, Wang Q, Wong E, Cordova-Palomera A, Smith EN, Szalma S, Zheng X, Esmaeeli S, Davis JW, Lai YP, Chen X, Justice AE, Leader JB, Mirshahi T, Carey DJ, Verma A, Sirugo G, Ritchie MD, Rader DJ, Povysil G, Goldstein DB, Kiryluk K, Pairo-Castineira E, Rawlik K, Pasko D, Walker S, Meynert A, Kousathanas A, Moutsianas L, Tenesa A, Caulfield M, Scott R, Wilson JF, Baillie JK, Butler-Laporte G, Nakanishi T, Lathrop M, Richards JB, Jones M, Balasubramanian S, Salerno W, Shuldiner AR, Marchini J, Overton JD, Habegger L, Cantor MN, Reid JG, Baras A, Abecasis GR, Ferreira MA. A catalog of associations between rare coding variants and COVID-19 outcomes. medRxiv 2021:2020.10.28.20221804. [PMID: 33655273 PMCID: PMC7924298 DOI: 10.1101/2020.10.28.20221804] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes coronavirus disease-19 (COVID-19), a respiratory illness that can result in hospitalization or death. We investigated associations between rare genetic variants and seven COVID-19 outcomes in 543,213 individuals, including 8,248 with COVID-19. After accounting for multiple testing, we did not identify any clear associations with rare variants either exome-wide or when specifically focusing on (i) 14 interferon pathway genes in which rare deleterious variants have been reported in severe COVID-19 patients; (ii) 167 genes located in COVID-19 GWAS risk loci; or (iii) 32 additional genes of immunologic relevance and/or therapeutic potential. Our analyses indicate there are no significant associations with rare protein-coding variants with detectable effect sizes at our current sample sizes. Analyses will be updated as additional data become available, with results publicly browsable at https://rgc-covid19.regeneron.com.
Collapse
Affiliation(s)
- J A Kosmicki
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - J E Horowitz
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - N Banerjee
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - R Lanche
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - A Marcketta
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - E Maxwell
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - X Bai
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - D Sun
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - J D Backman
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - D Sharma
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - H M Kang
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - C O'Dushlaine
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - A Yadav
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - A J Mansfield
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - A H Li
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - K Watanabe
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - L Gurski
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - S E McCarthy
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - A E Locke
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - S Khalid
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - S O'Keeffe
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - J Mbatchou
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - O Chazara
- Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, UK
| | - Y Huang
- Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, UK
| | - E Kvikstad
- Bristol Myers Squibb, Route 206 and Province Line Road, Princeton, NJ 08543, USA
| | - A O'Neill
- Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, UK
| | - P Nioi
- Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, UK
| | - M M Parker
- Alnylam Pharmaceuticals, 675 West Kendall St, Cambridge, MA 02142, USA
| | - S Petrovski
- Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, UK
| | - H Runz
- Biogen, 300 Binney St, Cambridge, MA 02142, USA
| | - J D Szustakowski
- Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, UK
| | - Q Wang
- Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, UK
| | - E Wong
- Biogen, 300 Binney St, Cambridge, MA 02142, USA
| | | | - E N Smith
- Takeda California Inc., 9625 Towne Centre Dr, San Diego, CA 92121, USA
| | - S Szalma
- Takeda California Inc., 9625 Towne Centre Dr, San Diego, CA 92121, USA
| | - X Zheng
- AbbVie, Inc., 1 N. Waukegan Rd, North Chicago, IL 60064, USA
| | - S Esmaeeli
- AbbVie, Inc., 1 N. Waukegan Rd, North Chicago, IL 60064, USA
| | - J W Davis
- AbbVie, Inc., 1 N. Waukegan Rd, North Chicago, IL 60064, USA
| | - Y-P Lai
- Pfizer, Inc., 1 Portland Street, Cambridge MA 02139, USA
| | - X Chen
- Pfizer, Inc., 1 Portland Street, Cambridge MA 02139, USA
| | | | | | | | | | - A Verma
- Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA
| | - G Sirugo
- Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA
| | - M D Ritchie
- Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA
| | - D J Rader
- Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA
| | - G Povysil
- Institute for Genomic Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA
| | - D B Goldstein
- Institute for Genomic Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA
- Department of Genetics & Development, Columbia University, New York, NY 10032, USA
| | - K Kiryluk
- Institute for Genomic Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA
- Division of Nephrology, Department of Medicine, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA
| | - E Pairo-Castineira
- Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK
- MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK
| | - K Rawlik
- Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK
| | - D Pasko
- Genomics England, London EC1M 6BQ, UK
| | - S Walker
- Genomics England, London EC1M 6BQ, UK
| | - A Meynert
- MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK
| | | | | | - A Tenesa
- Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK
- MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK
- Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, Teviot Place, Edinburgh EH8 9AG, UK
| | - M Caulfield
- Genomics England, London EC1M 6BQ, UK
- William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK
| | - R Scott
- Genomics England, London EC1M 6BQ, UK
- Great Ormond Street Hospital for Children NHS Foundation Trust, London WC1N 3JH, UK
| | - J F Wilson
- MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK
- Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, Teviot Place, Edinburgh EH8 9AG, UK
| | - J K Baillie
- Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK
- MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK
- Intensive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK
| | - G Butler-Laporte
- Lady Davis Institute, Jewish General Hospital, Montréal, Québec H3T 1E2, Canada
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Québec H3A 0G4, Canada
| | - T Nakanishi
- Lady Davis Institute, Jewish General Hospital, Montréal, Québec H3T 1E2, Canada
- Department of Human Genetics, McGill University, Montréal, Québec H3A 0G4, Canada
- Kyoto-McGill International Collaborative School in Genomic Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan
- Research Fellow, Japan Society for the Promotion of Science
| | - M Lathrop
- Department of Human Genetics, McGill University, Montréal, Québec H3A 0G4, Canada
- Canadian Centre for Computational Genomics, McGill University, Montréal, Québec H3A 0G4, Canada
| | - J B Richards
- Lady Davis Institute, Jewish General Hospital, Montréal, Québec H3T 1E2, Canada
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Québec H3A 0G4, Canada
- Department of Human Genetics, McGill University, Montréal, Québec H3A 0G4, Canada
- Department of Twins Research, King's College London, London WC2R 2LS, UK
| | - M Jones
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - S Balasubramanian
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - W Salerno
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - A R Shuldiner
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - J Marchini
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - J D Overton
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - L Habegger
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - M N Cantor
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - J G Reid
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - A Baras
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - G R Abecasis
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| | - M A Ferreira
- Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
| |
Collapse
|
28
|
Boella E, Bingham R, Cairns RA, Norreys P, Trines R, Scott R, Vranic M, Shukla N, Silva LO. Collisionless shock acceleration in the corona of an inertial confinement fusion pellet with possible application to ion fast ignition. Philos Trans A Math Phys Eng Sci 2021; 379:20200039. [PMID: 33280562 PMCID: PMC7741008 DOI: 10.1098/rsta.2020.0039] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Accepted: 10/19/2020] [Indexed: 06/12/2023]
Abstract
Two-dimensional particle-in-cell simulations are used to explore collisionless shock acceleration in the corona plasma surrounding the compressed core of an inertial confinement fusion pellet. We show that an intense laser pulse interacting with the long scale-length plasma corona is able to launch a collisionless shock around the critical density. The nonlinear wave travels up-ramp through the plasma reflecting and accelerating the background ions. Our results suggest that protons with characteristics suitable for ion fast ignition may be achieved in this way. This article is part of a discussion meeting issue 'Prospects for high gain inertial fusion energy (part 2)'.
Collapse
Affiliation(s)
- E. Boella
- Department of Physics, University of Lancaster, Lancaster, UK
- The Cockcroft Institute, Sci-Tech Daresbury, Warrington, UK
| | - R. Bingham
- STFC Rutherford Appleton Laboratory, Didcot, UK
- SUPA, Department of Physics, University of Strathclyde, Glasgow, UK
| | - R. A. Cairns
- School of Mathematics and Statistics, University of St Andrews, St Andrews, UK
| | - P. Norreys
- STFC Rutherford Appleton Laboratory, Didcot, UK
- Department of Physics, University of Oxford, Oxford, UK
| | - R. Trines
- STFC Rutherford Appleton Laboratory, Didcot, UK
| | - R. Scott
- STFC Rutherford Appleton Laboratory, Didcot, UK
| | - M. Vranic
- GoLP/Instituto de Plasmas e Fusão Nuclear, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal
| | - N. Shukla
- GoLP/Instituto de Plasmas e Fusão Nuclear, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal
| | - L. O. Silva
- GoLP/Instituto de Plasmas e Fusão Nuclear, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal
| |
Collapse
|
29
|
Watts G, Schwabe C, Scott R, Gladding P, Sullivan D, Baker J, Clifton P, Hamilton J, Given B, San Martin J, Melquist S, Knowles J, Goldberg I, Hegele R, Ballantyne C. RNAi inhibition of angiopoietin-like protein 3 (ANGPTL3) with ARO-ANG3 mimics the lipid and lipoprotein profile of familial combined hypolipidemia. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3331] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Elevated LDL-C and triglyceride rich lipoproteins (TRLs) are independent risk factors for cardiovascular disease (CVD). Genetic deficiency of angiopoietin-like protein 3 (ANGPTL3) is associated with reduced circulating levels of LDL-C, triglycerides (TGs), VLDL-C, HDL-C and reduced CVD risk, with no described adverse phenotype. ARO-ANG3 is a RNA interference drug designed to silence expression of ANGPTL3. Single doses of ARO-ANG3 have been shown to reduce ANGPTL3, TGs, VLDL-C and LDL-C in healthy volunteers (HVs, AHA 2019). We report the effects of multiple doses of ARO-ANG3 in HVs with a focus on the duration of action.
Methods
ARO-ANG3 was administered subcutaneously to HVs on days 1 and 29 at doses of 100, 200 or 300 mg (n=4 per group). Measured parameters included ANGPTL3, LDL-C, TGs, VLDL-C and HDL-C. Follow up is ongoing.
Results
All HVs have received both doses and follow-up is currently through week 16 (12 weeks after second dose). Mean nadir for ANGPTL3 levels occurred 2 weeks after the second dose (−83–93%) with minimal change for 200 and 300 mg but 16% recovery for 100 mg at week 16. Mean TGs and VLDL-C reached nadir earlier (3 wks, −61–65%) without apparent dose response and minimal change for any dose at wk 16. LDL-C nadir occurred 4–6 wks after the second dose (−45–54%), again with minimal evidence for dose response or change through wk 16. HDL-C was reduced 14–37% at wk 16. ARO-ANG3 was well tolerated without serious or severe adverse events or dropouts related to drug. The most common adverse events have been headache and upper respiratory infections.
Conclusions
Genetic deficiency of ANGPTL3 is a cause of familial combined hypolipemia and is associated with a decreased risk of CVD. Using RNAi to selectively suppress ANGPTL3 production reproduces these genetic effects with a duration of at least 12 weeks following a second dose and with good tolerability over 16 wks. ANGPTL3 inhibition results in lowering of LDL-C and TRLs which may confer protection against CVD in patients with atherogenic mixed dyslipidemia.
Funding Acknowledgement
Type of funding source: Private company. Main funding source(s): Arrowhead Pharmaceuticals
Collapse
Affiliation(s)
- G.F Watts
- University of Western Australia, Perth, Australia
| | - C Schwabe
- Auckland Clinical Studies, Auckland, New Zealand
| | - R Scott
- Christchurch Diabetes Centre, Division of Endocrinology, Diabetes, and Metabolism, Christchurch, New Zealand
| | - P Gladding
- Auckland City Hospital, Auckland, New Zealand
| | - D Sullivan
- Royal Prince Alfred Hospital, Sydney, Australia
| | - J Baker
- Middlemore Hospital, Auckland, New Zealand
| | - P Clifton
- Royal Adelaide Hospital, Adelaide, Australia
| | - J Hamilton
- Arrowhead Pharmaceuticals, Pasadena, United States of America
| | - B Given
- Arrowhead Pharmaceuticals, Pasadena, United States of America
| | - J San Martin
- Arrowhead Pharmaceuticals, Pasadena, United States of America
| | - S Melquist
- Arrowhead Pharmaceuticals, Pasadena, United States of America
| | - J.W Knowles
- School of Medicine, Stanford, United States of America
| | - I Goldberg
- NYU School of Medicine, NYU Langone Health, New York City, United States of America
| | - R Hegele
- University of Western Ontario, London, Canada
| | - C Ballantyne
- Baylor College of Medicine, Houston, United States of America
| |
Collapse
|
30
|
Schwabe C, Scott R, Sullivan D, Baker J, Clifton P, Hamilton J, Given B, San Martin J, Melquist S, Watts G, Goldberg I, Knowles J, Hegele R, Ballantyne C. RNA interference targeting apolipoprotein C-III with ARO-APOC3 in healthy volunteers mimics lipid and lipoprotein findings seen in subjects with inherited apolipoprotein C-III deficiency. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3330] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Individuals with triglycerides (TGs) ≥1,000 mg/dL (11.1 mmol/L) are at increased risk of acute pancreatitis. Genetic studies indicate that individuals with apolipoprotein C-3 (APOC3) loss-of-function mutations have low TGs, reduced cardiovascular risk and no observed adverse phenotype. RNA interference (RNAi) with ARO-APOC3 has shown deep and durable knockdown (KD) of APOC3 after single doses in healthy volunteers (HVs, presented at AHA 2019) with good tolerability. We report here initial results using multiple doses of ARO-APOC3 to silence APOC3 expression in HVs.
Methods
ARO-APOC3 was administered subcutaneously to HVs on days 1 and 29 at doses of 10, 25 or 50 mg (n=4 per group). Measured parameters included plasma concentrations of APOC3, LDL-C, TGs, VLDL-C and HDL-C.
Results
All HVs have received both doses and follow-up for most parameters is available through week (wk) 14 (10 wks after second dose) for the 10 and 25 mg doses and through wk 10 for 50 mg. Mean nadir for APOC3 levels occurred at wk 3 for 10 mg (−73%) and remained similar at wk 10 (−66%), at wk 6 for 25 mg (−90%) with no change at wk 10 and at wk 2 for 50 mg (−94%) unchanged at wk 8. TGs fell faster in the 50 mg group (wk 1: 10 mg −41%; 25 mg −47%; 50 mg −72%). By wk 6 the 25 and 50 mg results were similar (−68% and −74%, respectively) and remained similar through wk 14. 10 mg was less active with a nadir of −56% and mean reductions between 42% and 56% post-nadir. VLDL-C values mirrored TGs. LDL-C reductions were more modest and did not manifest a dose response. Mean nadirs (−23–26%) occurred 4–6 wks after the first dose, again with minimal change through 10–14 wks of follow-up. Consistent with genetic studies, HDL-C increased to a maximum at approximately wk 8 (10 mg +42%, 25 mg +48%, 50 mg +84%). ARO-APOC3 was well tolerated without serious or severe adverse events or dropouts related to drug. The most common adverse events were mild injection site AEs and headache.
Conclusions
Genetic deficiency of APOC3 is associated with substantial reductions in TGs, VLDL-C and increases in HDL-C without an adverse phenotype. Using RNAi to selectively suppress APOC3 production mimics these lipid and lipoprotein effects, with a duration of at least 10 weeks following a second dose and with good tolerability over 16 wks using doses ranging from 10 to 50 mg. Investigation of optimal dosing regimen is ongoing, especially with respect to dosing interval. This therapeutic approach has potential for treating patients with chylomicronemia at risk of pancreatitis.
Funding Acknowledgement
Type of funding source: Private company. Main funding source(s): Arrowhead Pharmaceuticals
Collapse
Affiliation(s)
- C Schwabe
- Auckland Clinical Studies, Auckland, New Zealand
| | - R Scott
- Christchurch Diabetes Centre, Diabetes Research Institute, Christchurch, New Zealand
| | - D Sullivan
- Royal Prince Alfred Hospital, Camperdown, New Zealand
| | - J Baker
- Middlemore Hospital, Auckland, New Zealand
| | - P Clifton
- Royal Adelaide Hospital, Adelaide, Australia
| | - J Hamilton
- Arrowhead Pharmaceuticals, Pasadena, United States of America
| | - B Given
- Arrowhead Pharmaceuticals, Pasadena, United States of America
| | - J San Martin
- Arrowhead Pharmaceuticals, Pasadena, United States of America
| | - S Melquist
- Arrowhead Pharmaceuticals, Pasadena, United States of America
| | - G.F Watts
- University of Western Australia, Perth, Australia
| | - I Goldberg
- NYU School of Medicine, NYU Langone Health, Division of Endocrinology, Diabetes, and Metabolism, New York City, United States of America
| | - J.W Knowles
- School of Medicine, Stanford, United States of America
| | - R Hegele
- University of Western Ontario, London, Canada
| | - C Ballantyne
- Baylor College of Medicine, Houston, United States of America
| |
Collapse
|
31
|
Neal S, Morin S, Werner M, Gueye NA, Pirtea P, Patounakis G, Scott R, Goodman L. Three-dimensional ultrasound diagnosis of adenomyosis is not associated with adverse pregnancy outcome following single thawed euploid blastocyst transfer: prospective cohort study. Ultrasound Obstet Gynecol 2020; 56:611-617. [PMID: 32349167 DOI: 10.1002/uog.22065] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/19/2019] [Revised: 04/20/2020] [Accepted: 04/24/2020] [Indexed: 06/11/2023]
Abstract
OBJECTIVES The objectives of this study were (1) to assess the prevalence of ultrasound (US) features of adenomyosis in an infertile population undergoing in-vitro fertilization (IVF), (2) to define the inter- and intrarater agreement of three-dimensional (3D) US assessment of adenomyosis, and (3) to evaluate sonographic features of adenomyosis with respect to pregnancy outcome following transfer of a single thawed euploid blastocyst. METHODS This was a prospective cohort study. Subjects scheduled to undergo a single thawed euploid blastocyst transfer between April and December 2017 at a large IVF center were eligible for inclusion. Enrolled subjects underwent endometrial preparation for frozen embryo transfer. 3D-US was performed on the day prior to embryo transfer, with images stored for subsequent evaluation. Subjects then underwent transfer of a single thawed euploid blastocyst, and pregnancy outcomes were collected. All 3D-US volumes were de-identified and reviewed independently by five reproductive endocrinologists/infertility specialists with expertise in gynecological US for the presence of seven sonographic features of adenomyosis: global uterine enlargement, myometrial wall asymmetry, heterogeneous echogenicity, irregular junctional zone, myometrial cysts, fan-shaped shadowing and ill-defined myometrial lesions. Adenomyosis was considered to be present if the majority of the reviewers noted at least one of the seven sonographic features. Inter- and intrarater agreement was evaluated using Fleiss's kappa. Clinical and cycle characteristics of subjects with and those without adenomyosis were compared. The primary outcome of interest was live birth rate. Secondary outcomes included clinical pregnancy rate and miscarriage rate. Logistic regression analysis was performed to account for potential confounders. RESULTS A total of 648 subjects were included. The prevalence of adenomyosis on US was 15.3% (99/648). On retrospective chart review, very few patients with adenomyosis had symptoms. The inter- and intrarater agreement amongst five independent specialists conducting the 3D-US assessments of adenomyosis were poor (κ = 0.23) and moderate (κ = 0.58), respectively. Subjects with adenomyosis were older (37.1 vs 35.9 years, P = 0.02) and more likely to undergo a gonadotropin-releasing hormone agonist downregulation protocol when compared with those without adenomyosis (12.1% vs 5.1%, P = 0.02). Clinical pregnancy (80.0% vs 75.0%) and live birth (69.5% vs 66.5%) rates were similar between the groups. When adjusting for potential confounders, there was no difference in the rate of clinical pregnancy (adjusted odds ratio (aOR), 1.47 (95% CI, 0.85-2.56)), miscarriage (aOR, 1.3 (95% CI, 0.62-2.72)) or live birth (aOR, 1.28 (95% CI, 0.78-2.08)) between subjects with and those without adenomyosis. No individual sonographic marker of adenomyosis was predictive of pregnancy outcome. CONCLUSIONS The inter-rater agreement of 3D-US assessment of adenomyosis is poor. Furthermore, sonographic markers of adenomyosis in asymptomatic patients may not be associated with altered pregnancy outcome following transfer of a single thawed euploid blastocyst. These findings suggest that routine screening for asymptomatic adenomyosis in an unselected infertile patient population undergoing frozen embryo transfer may not be warranted. © 2020 International Society of Ultrasound in Obstetrics and Gynecology.
Collapse
Affiliation(s)
- S Neal
- IVI/RMA New Jersey, Basking Ridge, NJ, USA
| | - S Morin
- IVI/RMA New Jersey, Basking Ridge, NJ, USA
| | - M Werner
- IVI/RMA New Jersey, Basking Ridge, NJ, USA
| | - N-A Gueye
- IVI/RMA Pennsylvania, Lehigh Valley, PA, USA
| | - P Pirtea
- IVI/RMA New Jersey, Basking Ridge, NJ, USA
| | | | - R Scott
- IVI/RMA New Jersey, Basking Ridge, NJ, USA
| | - L Goodman
- Division of Reproductive Endocrinology and Infertility, University of North Carolina, Chapel Hill, NC, USA
| |
Collapse
|
32
|
Gunner RM, Wilson RP, Holton MD, Scott R, Hopkins P, Duarte CM. A new direction for differentiating animal activity based on measuring angular velocity about the yaw axis. Ecol Evol 2020; 10:7872-7886. [PMID: 32760571 PMCID: PMC7391348 DOI: 10.1002/ece3.6515] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2019] [Revised: 06/08/2020] [Accepted: 06/09/2020] [Indexed: 12/11/2022] Open
Abstract
The use of animal-attached data loggers to quantify animal movement has increased in popularity and application in recent years. High-resolution tri-axial acceleration and magnetometry measurements have been fundamental in elucidating fine-scale animal movements, providing information on posture, traveling speed, energy expenditure, and associated behavioral patterns. Heading is a key variable obtained from the tandem use of magnetometers and accelerometers, although few field investigations have explored fine-scale changes in heading to elucidate differences in animal activity (beyond the notable exceptions of dead-reckoning).This paper provides an overview of the value and use of animal heading and a prime derivative, angular velocity about the yaw axis, as an important element for assessing activity extent with potential to allude to behaviors, using "free-ranging" Loggerhead turtles (Caretta caretta) as a model species.We also demonstrate the value of yaw rotation for assessing activity extent, which varies over the time scales considered and show that various scales of body rotation, particularly rate of change of yaw, can help resolve differences between fine-scale behavior-specific movements. For example, oscillating yaw movements about a central point of the body's arc implies bouts of foraging, while unusual circling behavior, indicative of conspecific interactions, could be identified from complete revolutions of the longitudinal axis.We believe this approach should help identification of behaviors and "space-state" approaches to enhance our interpretation of behavior-based movements, particularly in scenarios where acceleration metrics have limited value, such as for slow-moving animals.
Collapse
Affiliation(s)
- Richard M. Gunner
- Swansea Lab for Animal Movement, BiosciencesCollege of ScienceSwansea UniversitySwanseaUK
| | - Rory P. Wilson
- Swansea Lab for Animal Movement, BiosciencesCollege of ScienceSwansea UniversitySwanseaUK
| | - Mark D. Holton
- Swansea Lab for Animal Movement, BiosciencesCollege of ScienceSwansea UniversitySwanseaUK
| | - Rebecca Scott
- Future Ocean Cluster of ExcellenceGEOMAR Helmholtz Centre for Ocean ResearchKielGermany
- Natural Environmental Research Council, Polaris HouseSwindonUK
| | - Phil Hopkins
- Swansea Lab for Animal Movement, BiosciencesCollege of ScienceSwansea UniversitySwanseaUK
| | - Carlos M. Duarte
- Red Sea Research CentreKing Abdullah University of Science and TechnologyThuwalSaudi Arabia
| |
Collapse
|
33
|
Kondrashev S, Beebe E, Kanesue T, Okamura M, Ritter J, Scott R. Design of target irradiation and diagnostic chamber to study ps-laser generated plasma as a source of singly charged ions for external injection into an electron beam ion source. Rev Sci Instrum 2020; 91:023320. [PMID: 32113381 DOI: 10.1063/1.5127833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/13/2019] [Accepted: 02/01/2020] [Indexed: 06/10/2023]
Abstract
High repetition-rate (∼10 kHz) ps-lasers are becoming available on the market with reasonable cost and may offer several advantages compared to ns-lasers by generating nearly continuous beams of singly charged ions appropriate for the "slow" injection mode into the Electron Beam Ion Source (EBIS). To evaluate these advantages, we will perform studies of a ps-laser generated plasma using a laser with a pulse duration of 8 ps and energy up to 5 mJ per pulse. A vacuum chamber equipped with a 3D target positioner, a focusing lens, and a Faraday Cup has been designed and built for this study. Lens-to-target distance variations have been measured using a laser tracker over the whole range of horizontal and vertical translation for all five targets we will use. The variations were found to be within ±150 µm. This degree of "target flatness" should be acceptable for our experimental conditions. Ion currents and ion pulse durations of various elements (from Al to Ta) will be measured for different target irradiation conditions (focal spot size and laser pulse energy). The results obtained will allow us to specify all parameters and geometry of a laser ion source based on a ps-laser to provide external ion injection into the relativistic heavy ion collider EBIS.
Collapse
Affiliation(s)
- S Kondrashev
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - E Beebe
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - T Kanesue
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - M Okamura
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J Ritter
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - R Scott
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| |
Collapse
|
34
|
Arkwright AC, Archibald E, Fahlman A, Holton MD, Crespo-Picazo JL, Cabedo VM, Duarte CM, Scott R, Webb S, Gunner RM, Wilson RP. Behavioral Biomarkers for Animal Health: A Case Study Using Animal-Attached Technology on Loggerhead Turtles. Front Ecol Evol 2020. [DOI: 10.3389/fevo.2019.00504] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Davis T, Singh J, Lance JG, Latiolais L, Kevil C, Bodily J, Sapp M, Scott R, Weinberger P, Vanchiere J, Arnold C. COVID-19 Community Testing In Rural Areas: A Partnership between an Academic Medical Center and Community Clinics. J Community Med Health Educ 2020; 10:686. [PMID: 35573826 PMCID: PMC9106223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- T Davis
- Department of Medicine, LSU Health - Shreveport, Shreveport, Louisiana, USA
| | - J Singh
- Department of Medicine, LSU Health - Shreveport, Shreveport, Louisiana, USA
| | - JG Lance
- Department of Medicine, LSU Health - Shreveport, Shreveport, Louisiana, USA
| | - L Latiolais
- Department of Microbiology and Immunology, LSU Health - Shreveport, Shreveport, Louisiana, USA
| | - C Kevil
- Department of Pathology, School of Graduate Studies, LSU Health - Shreveport, Shreveport, Louisiana, USA
| | - J Bodily
- Department of Microbiology and Immunology, LSU Health - Shreveport, Shreveport, Louisiana, USA
| | - M Sapp
- Department of Microbiology and Immunology, LSU Health - Shreveport, Shreveport, Louisiana, USA
| | - R Scott
- Department of Microbiology and Immunology, LSU Health - Shreveport, Shreveport, Louisiana, USA
| | - P Weinberger
- Department of Otolaryngology, LSU Health - Shreveport, Shreveport, Louisiana, USA
| | - J Vanchiere
- Department of Pediatrics, LSU Health - Shreveport, Shreveport, Louisiana, USA
| | - C Arnold
- Department of Medicine, LSU Health - Shreveport, Shreveport, Louisiana, USA,Corresponding author: Connie Arnold, Department of Medicine, LSU Health-Shreveport, 1501 Kings Highway, Shreveport, Louisiana, USA, Tel: 3186754324;
| |
Collapse
|
36
|
Scott R, Hawarden A, Russell B, Edmondson RJ. Decision-Making in Gynaecological Oncology Multidisciplinary Team Meetings: A Cross-Sectional, Observational Study of Ovarian Cancer Cases. Oncol Res Treat 2019; 43:70-77. [PMID: 31743932 DOI: 10.1159/000504260] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2019] [Accepted: 10/16/2019] [Indexed: 11/19/2022]
Abstract
INTRODUCTION Multidisciplinary team (MDT) meetings are widely used across the UK to provide expert decisions and improve cancer outcomes. However, little is known about the underlying mechanisms of MDT decision-making. We investigated how decisions are made regarding the management of advanced ovarian cancer in gynaecological oncology MDT meetings. METHODS A cross-sectional observational study was performed, focussing on 41/ 223 MDT case discussions across six hospitals. The validated MDT-MODe tool was adapted to increase relevance to gynaecological oncology. Case information and contributions from seven disciplines were rated on a five-point Likert scale. Spearman's correlation investigated relationships between factors and an exploratory factor analysis examined the underlying structure of MDT discussion. RESULTS Forty-one MDT decisions were made for patients with FIGO Stage III/IV ovarian cancer. MDT case discussions were structured by four factors: "Clinical Presentation," "Patient Factors," "Chair's Direction" and "Input from Other Specialties." Nurses were often quiet but facilitated discussion of patient factors. Junior doctors were not involved in MDT decision-making. CONCLUSIONS The decision-making process in MDT meetings is driven by four underlying factors, the most significant of which represents patient history, tumour markers, images and radiologist input. Patient factors were underrepresented, and nurses should be empowered to overcome this.
Collapse
Affiliation(s)
- Rebecca Scott
- Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester, United Kingdom
| | - Amy Hawarden
- Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester, United Kingdom
- Department of Obstetrics and Gynaecology, Manchester Academic Health Science Centre, St Mary's Hospital, Central Manchester NHS Foundation Trust, Manchester, United Kingdom
| | - Bryn Russell
- Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester, United Kingdom
| | - Richard J Edmondson
- Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester, United Kingdom,
- Department of Obstetrics and Gynaecology, Manchester Academic Health Science Centre, St Mary's Hospital, Central Manchester NHS Foundation Trust, Manchester, United Kingdom,
| |
Collapse
|
37
|
Scott R, Ellis L, Khanom A, Rhydderch M, Richardson G, Russell D, Russell I, Snooks H. Health experiences of asylum seekers and refugees in Wales. Eur J Public Health 2019. [DOI: 10.1093/eurpub/ckz186.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
There are concerns that people seeking sanctuary (asylum seekers and refugees) in Wales, UK, have unmet health needs and face difficulties accessing services, but little collated evidence. This study addressed this gap to inform policy and practice in reducing health inequities. It aimed to: investigate the health, wellbeing and healthcare experiences of adults seeking sanctuary in Wales, including the views of healthcare recipients and providers; and establish what helped or hindered the healthcare experiences of those seeking sanctuary. It is the most comprehensive study of this population in Wales.
A mixed-method approach was taken, including a literature search, a cross-sectional survey of 210 adults seeking sanctuary, telephone interviews with 32 health professionals and third sector support workers, and 8 focus groups including 57 people seeking sanctuary and those supporting them.
Eight trained volunteer peer researchers, themselves asylum seekers or refugees, administered the surveys. Interviews were digitally recorded, transcribed and analysed using a standard framework.
The literature search identified 5 themes that help or hinder people seeking sanctuary to access healthcare. The survey found 79% of respondents attended an initial health assessment on arriving in Wales, with 94% currently registered with Primary healthcare. 64% reported difficulties in accessing health services. Awareness of services was mixed, with 66% having used healthcare in working hours (planned) and 28% out of hours (unplanned).
Mainstream health professionals felt they lack capacity to deliver care effectively due to time and other pressures on the healthcare system and the need for appropriate translation/interpretation services.
This study triangulates the experiences of people seeking sanctuary with those providing healthcare and general support. Peer researchers maximised sanctuary seekers’ participation. Many of its methods and findings have relevance to other countries in Europe.
Key messages
Improving health equity is key to realising Wales’ ambition to become a Nation of Sanctuary. Peer Researchers enabled participation by sanctuary seekers and revealed useful findings to steer future policy and practice.
Collapse
Affiliation(s)
- R Scott
- Policy & International Health, Public Health Wales, Cardiff, UK
| | - L Ellis
- Policy & International Health, Public Health Wales, Cardiff, UK
| | - A Khanom
- Patient and Population Health and Informatics, Swansea University, Swansea, UK
| | - M Rhydderch
- Displaced People in Action, Displaced People in Action, Cardiff, UK
| | - G Richardson
- Policy & International Health, Public Health Wales, Cardiff, UK
| | - D Russell
- Patient and Population Health and Informatics, Swansea University, Swansea, UK
| | - I Russell
- Patient and Population Health and Informatics, Swansea University, Swansea, UK
| | - H Snooks
- Patient and Population Health and Informatics, Swansea University, Swansea, UK
| |
Collapse
|
38
|
Khanom A, Evans B, Alonazi W, Glendenning A, Jones M, John A, Khan T, Kingston MR, Manning C, Moyo S, Porter A, Rhydderch M, Rungua G, Russell D, Russell I, Scott R, Williams V, Snooks H. OP4 Accessing unplanned and emergency health services – experiences of asylum seekers, refused asylum seekers and refugees living in wales. J Accid Emerg Med 2019. [DOI: 10.1136/emermed-2019-999abs.4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundNumbers of asylum seekers and refugees living in Wales have increased sharply. Many are liable to have unmet health needs and difficulty accessing services. We investigated the experience of, and access to, unplanned and emergency health services by asylum seekers, refugees and those refused asylum living in Wales.MethodWe surveyed 210 asylum seekers, refused asylum seekers and refugees and conducted eight focus groups with 57 participants (with interpreters present when necessary) to explore experiences. We used descriptive statistics to analyse survey data and framework analyses to analyse interview data.ResultsSurvey data showed awareness of unscheduled health services was mixed. Best known was the 999 ambulance service (72% reportedly had heard of and could contact this outside daytime hours). NHS111 was familiar to 36% but just a quarter (26%) had heard of and could contact GP out-of-hours services. Fewer than half of respondents (44%) knew of the Emergency Department. 26% reported using a health service out-of-hours. Focus group respondents with little English reported difficulty explaining their health needs, particularly in emergencies and when seeking telephone help through 999 and 111 calls. Others said they used emergency services if they did not know how to access routine and out-of-hours care or if they felt their efforts to see a GP did not resolve their problem.ConclusionLanguage barriers and poor knowledge of UK health systems mean asylum seekers, refused asylum seekers and refugees use emergency health services to meet needs which could be seen and treated in routine primary services. Language barriers using phone lines may also result in paramedic attendance or conveyance to Emergency Departments because health needs are not clearly identified. Better information and support may help this population access services which match their needs and support their health more effectively.
Collapse
|
39
|
Scott R, Goulden T, Letman M, Hayward J, Jamieson R. Long-term evaluation of the impact of urbanization on chloride levels in lakes in a temperate region. J Environ Manage 2019; 244:285-293. [PMID: 31128333 DOI: 10.1016/j.jenvman.2019.05.029] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/20/2018] [Revised: 05/03/2019] [Accepted: 05/05/2019] [Indexed: 06/09/2023]
Abstract
The application of road salts for winter de-icing of roadways in cold regions has been demonstrated to increase chloride (Cl) concentrations in nearby surface waters and have a negative impact on aquatic organisms and processes. In addition to toxicity to aquatic organisms, high concentrations of Cl in lakes can alter mixing processes, resulting in prolonged anoxic conditions and associated water quality degradation. Elevated concentrations of Cl in freshwater environments in cold regions is a well-documented phenomenon, but few studies have undertaken a long-term evaluation of the impact of urbanization on lakes. In this paper, nine lakes in the Halifax region of Nova Scotia, Canada, were monitored over 35 years to observe Cl concentrations prior to, during, and after urbanizing development. Cl concentrations were observed to increase in most study lakes over the monitoring period and all nine exhibited seasonal trending in response to winter de-icing activities. Six of the lakes achieved a steady-state Cl level after an initial increase in response to development activities, two are potentially still in transition, and one was unaffected by development activities. Watershed land use was found to be a good predictor of the springtime concentration of Cl and can help to inform decision-making surrounding development activities. When the percent of developed land was 25% or more, the Cl concentrations tended to exceed Canadian freshwater quality guidelines for the protection of aquatic life.
Collapse
Affiliation(s)
- R Scott
- Centre for Water Resources Studies, Dalhousie University Halifax, NS, B3H 4R2, Canada
| | - T Goulden
- Centre for Water Resources Studies, Dalhousie University Halifax, NS, B3H 4R2, Canada
| | - M Letman
- Centre for Water Resources Studies, Dalhousie University Halifax, NS, B3H 4R2, Canada
| | - J Hayward
- Centre for Water Resources Studies, Dalhousie University Halifax, NS, B3H 4R2, Canada
| | - R Jamieson
- Centre for Water Resources Studies, Dalhousie University Halifax, NS, B3H 4R2, Canada.
| |
Collapse
|
40
|
Scott R, Muller S, Boddana P, SINGH A. MON-048 A new report of glomerulonephritis associated with the use of Talimogene laherparepvec immunotherapy. Kidney Int Rep 2019. [DOI: 10.1016/j.ekir.2019.05.835] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
41
|
Wilson RP, Börger L, Holton MD, Scantlebury DM, Gómez-Laich A, Quintana F, Rosell F, Graf PM, Williams H, Gunner R, Hopkins L, Marks N, Geraldi NR, Duarte CM, Scott R, Strano MS, Robotka H, Eizaguirre C, Fahlman A, Shepard ELC. Estimates for energy expenditure in free-living animals using acceleration proxies: A reappraisal. J Anim Ecol 2019; 89:161-172. [PMID: 31173339 DOI: 10.1111/1365-2656.13040] [Citation(s) in RCA: 92] [Impact Index Per Article: 18.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2018] [Accepted: 04/10/2019] [Indexed: 11/30/2022]
Abstract
It is fundamentally important for many animal ecologists to quantify the costs of animal activities, although it is not straightforward to do so. The recording of triaxial acceleration by animal-attached devices has been proposed as a way forward for this, with the specific suggestion that dynamic body acceleration (DBA) be used as a proxy for movement-based power. Dynamic body acceleration has now been validated frequently, both in the laboratory and in the field, although the literature still shows that some aspects of DBA theory and practice are misunderstood. Here, we examine the theory behind DBA and employ modelling approaches to assess factors that affect the link between DBA and energy expenditure, from the deployment of the tag, through to the calibration of DBA with energy use in laboratory and field settings. Using data from a range of species and movement modes, we illustrate that vectorial and additive DBA metrics are proportional to each other. Either can be used as a proxy for energy and summed to estimate total energy expended over a given period, or divided by time to give a proxy for movement-related metabolic power. Nonetheless, we highlight how the ability of DBA to predict metabolic rate declines as the contribution of non-movement-related factors, such as heat production, increases. Overall, DBA seems to be a substantive proxy for movement-based power but consideration of other movement-related metrics, such as the static body acceleration and the rate of change of body pitch and roll, may enable researchers to refine movement-based metabolic costs, particularly in animals where movement is not characterized by marked changes in body acceleration.
Collapse
Affiliation(s)
- Rory P Wilson
- Department of Biosciences, Swansea University, Swansea, UK
| | - Luca Börger
- Department of Biosciences, Swansea University, Swansea, UK
| | - Mark D Holton
- Department of Computing Science, Swansea University, Swansea, UK
| | - D Michael Scantlebury
- School of Biological Sciences, Institute for Global Food Security, Queen's University Belfast, Belfast, UK
| | - Agustina Gómez-Laich
- Instituto de Biología de Organismos Marinos IBIOMAR-CONICET, Puerto Madryn, Argentina
| | - Flavio Quintana
- Instituto de Biología de Organismos Marinos IBIOMAR-CONICET, Puerto Madryn, Argentina
| | - Frank Rosell
- Department of Natural Sciences and Environmental Health, Faculty of Technology, Natural Sciences, and Maritime Sciences, University of South-Eastern Norway, Bø i Telemark, Norway
| | - Patricia M Graf
- Department of Forestry and Renewable Forest Resources, Biotechnical Faculty, University of Ljubljana, Ljubljana, Slovenia.,Institute of Wildlife Biology and Game Management, University of Natural Resources and Life Sciences, Vienna, Vienna, Austria
| | | | - Richard Gunner
- Department of Biosciences, Swansea University, Swansea, UK
| | - Lloyd Hopkins
- Department of Biosciences, Swansea University, Swansea, UK
| | - Nikki Marks
- School of Biological Sciences, Institute for Global Food Security, Queen's University Belfast, Belfast, UK
| | - Nathan R Geraldi
- Red Sea Research Centre and Computational Biology Research Center, King Abdullah University of Science and Technology, Thuwal, Saudi Arabia
| | - Carlos M Duarte
- Red Sea Research Centre and Computational Biology Research Center, King Abdullah University of Science and Technology, Thuwal, Saudi Arabia
| | - Rebecca Scott
- Geomar Helmholz Centre for Ocean Research Kiel, Kiel, Germany
| | - Michael S Strano
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
| | | | - Christophe Eizaguirre
- School of Biological and Chemical Sciences, Queen Mary University of London, London, UK
| | - Andreas Fahlman
- Departamento de Investigación, Fundación Oceanogràfic de la Comunidad Valenciana, Valencia, Spain
| | - Emily L C Shepard
- Department of Biosciences, Swansea University, Swansea, UK.,Max Planck Institute for Ornithology, Radolfzell, Germany
| |
Collapse
|
42
|
Kandil H, Scott R, Mathavakkhannan S, Van de Velde S, Naji O. Appropriate dosing regimen of temocillin in patients with underlying kidney diseases: a retrospective study at a large District Hospital in the UK. J Antimicrob Chemother 2019; 74:530-531. [PMID: 30403773 DOI: 10.1093/jac/dky449] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Hala Kandil
- West Hertfordshire Hospitals NHS Trust, Watford General Hospital, Vicarage Road, Watford, Hertfordshire, UK
| | - Rebecca Scott
- East and North Hertfordshire NHS Trust, Lister Hospital, Coreys Mill Lane, Stevenage, Hertfordshire, UK
| | - Suresh Mathavakkhannan
- East and North Hertfordshire NHS Trust, Lister Hospital, Coreys Mill Lane, Stevenage, Hertfordshire, UK
| | | | - Omar Naji
- Barts and London School of Medicine and Dentistry, Turner Street, Whitechapel, London, UK
| |
Collapse
|
43
|
Cao J, Waldman B, O’Connell R, Sullivan D, Gebski V, Marschner I, Scott R, Taskinen M, Simes J, McGill N, Jenkins A, Keech A. Baseline and Short-Term Change in Plasma Uric Acid on Fenofibrate Predict Cardiovascular Risk: A Post Hoc Analysis of FIELD. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.06.354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
44
|
Shah M, Paulson D, Bassett R, Herring D, Scott R, Herrera M, James N. PRELIMINARY EVIDENCE FOR A FEASIBLE DEMENTIA CAREGIVER SUPPORT GROUP IN A PRIMARY CARE SETTING. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.1725] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- M Shah
- University of Central Florida
| | | | | | | | - R Scott
- University of Central Florida
| | | | - N James
- University of Central Florida
| |
Collapse
|
45
|
Scott R, Paulson D, Camacho S. VALIDATION OF THE PAULSON-LICHTENBERG FRAILTY INDEX AGAINST THE DEFICIT ACCUMULATION MODEL. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.2586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- R Scott
- University of Central Florida
| | | | | |
Collapse
|
46
|
Vondrasek RC, Dickerson CA, Hendricks M, Ostroumov P, Pardo R, Savard G, Scott R, Zinkann G. Erratum: "Charge breeding of radioactive isotopes at the CARIBU facility with an electron beam ion source" [Rev. Sci. Instrum. 89, 052402 (2018)]. Rev Sci Instrum 2018; 89:109901. [PMID: 30399764 DOI: 10.1063/1.5063798] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/01/2018] [Accepted: 10/01/2018] [Indexed: 06/08/2023]
Affiliation(s)
- R C Vondrasek
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - C A Dickerson
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - M Hendricks
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - P Ostroumov
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - R Pardo
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - G Savard
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - R Scott
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - G Zinkann
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| |
Collapse
|
47
|
Brant A, Dhillon P, Hull S, Coleman M, Ye P, Lotke P, Folan J, Alintah P, Scott R. Integration of HIV preexposure prophylaxis (PrEP) services with family planning services: an evaluation using the RE-AIM framework. Contraception 2018. [DOI: 10.1016/j.contraception.2018.07.120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
48
|
Tessler M, Paul M, Halfon S, Meyer BS, Pardo R, Purtschert R, Rehm KE, Scott R, Weigand M, Weissman L, Almaraz-Calderon S, Avila ML, Baggenstos D, Collon P, Hazenshprung N, Kashiv Y, Kijel D, Kreisel A, Reifarth R, Santiago-Gonzalez D, Shor A, Silverman I, Talwar R, Veltum D, Vondrasek R. Stellar ^{36,38}Ar(n,γ)^{37,39}Ar Reactions and Their Effect on Light Neutron-Rich Nuclide Synthesis. Phys Rev Lett 2018; 121:112701. [PMID: 30265109 DOI: 10.1103/physrevlett.121.112701] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/05/2018] [Revised: 07/24/2018] [Indexed: 06/08/2023]
Abstract
The ^{36}Ar(n,γ)^{37}Ar (t_{1/2}=35 d) and ^{38}Ar(n,γ)^{39}Ar (269 yr) reactions were studied for the first time with a quasi-Maxwellian (kT∼47 keV) neutron flux for Maxwellian average cross section (MACS) measurements at stellar energies. Gas samples were irradiated at the high-intensity Soreq applied research accelerator facility-liquid-lithium target neutron source and the ^{37}Ar/^{36}Ar and ^{39}Ar/^{38}Ar ratios in the activated samples were determined by accelerator mass spectrometry at the ATLAS facility (Argonne National Laboratory). The ^{37}Ar activity was also measured by low-level counting at the University of Bern. Experimental MACS of ^{36}Ar and ^{38}Ar, corrected to the standard 30 keV thermal energy, are 1.9(3) and 1.3(2) mb, respectively, differing from the theoretical and evaluated values published to date by up to an order of magnitude. The neutron-capture cross sections of ^{36,38}Ar are relevant to the stellar nucleosynthesis of light neutron-rich nuclides; the two experimental values are shown to affect the calculated mass fraction of nuclides in the region A=36-48 during the weak s process. The new production cross sections have implications also for the use of ^{37}Ar and ^{39}Ar as environmental tracers in the atmosphere and hydrosphere.
Collapse
Affiliation(s)
- M Tessler
- Racah Institute of Physics, Hebrew University, Jerusalem 91904, Israel
| | - M Paul
- Racah Institute of Physics, Hebrew University, Jerusalem 91904, Israel
| | | | - B S Meyer
- Department of Physics and Astronomy, Clemson University, Clemson, South Carolina 29634, USA
| | - R Pardo
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - R Purtschert
- Physics Institute, University of Bern, 3012 Bern, Switzerland
| | - K E Rehm
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - R Scott
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - M Weigand
- Goethe University Frankfurt, Frankfurt 60438, Germany
| | | | | | - M L Avila
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - D Baggenstos
- Physics Institute, University of Bern, 3012 Bern, Switzerland
| | - P Collon
- Department of Physics, University of Notre Dame, Notre Dame, Indiana 46556, USA
| | | | - Y Kashiv
- Department of Physics, University of Notre Dame, Notre Dame, Indiana 46556, USA
| | - D Kijel
- Soreq NRC, Yavne 81800, Israel
| | | | - R Reifarth
- Goethe University Frankfurt, Frankfurt 60438, Germany
| | - D Santiago-Gonzalez
- Argonne National Laboratory, Argonne, Illinois 60439, USA
- Department of Physics and Astronomy, Louisiana State University, Baton Rouge, Louisiana 70803, USA
| | - A Shor
- Soreq NRC, Yavne 81800, Israel
| | | | - R Talwar
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - D Veltum
- Goethe University Frankfurt, Frankfurt 60438, Germany
| | - R Vondrasek
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| |
Collapse
|
49
|
Neal S, Goodman L, Morin S, Werner M, Gueye N, Tiegs A, Pirtea P, Scott R. T-shaped uterine cavity morphology as assessed by three-dimensional ultrasound (3D US) is associated with lower sustained implantation rates and higher clinical loss rates following frozen embryo transfer. Fertil Steril 2018. [DOI: 10.1016/j.fertnstert.2018.07.393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
50
|
Tiegs A, Landis J, Garrido N, Scott R, Hotaling J. Total motile sperm count trend over time across two continents: evaluation of semen analyses from 119,972 infertile men. Fertil Steril 2018. [DOI: 10.1016/j.fertnstert.2018.07.093] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|